image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
afc67efd98d1174a57c6e260361ddc98aa16385e39ac19c064b4c35d1cf562db.png | simple | <table><tr><td> </td><td>2011 total<sup>a</sup></td><td>2011 indoor tanned</td><td>2013 total<sup>a</sup></td><td>2013 indoor tanned</td><td>Chi-square</td><td><i>P</i> value</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Female</td><td>8,316</td><td>1420 (17.6%)</td><td>8004</td><td>882 (11.7%)</td><td>10.2</td><td>0.002</td></tr><tr><td> Male</td><td>7,293</td><td>442 (6.4%)</td><td>7180</td><td>276 (3.8%)</td><td>9.64</td><td>0.002</td></tr><tr><td> Combined</td><td>15,609</td><td>1862 (12%)</td><td>15,184</td><td>1158 (7.7%)</td><td>11.37</td><td><0.0001</td></tr><tr><td>Grade Level</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 8th grade</td><td>6,035</td><td>332 (5.2%)</td><td>6,186</td><td>228 (3.3%)</td><td>7.8</td><td>0.005</td></tr><tr><td> 10th grade</td><td>5,389</td><td>669 (11.9%)</td><td>5,069</td><td>417 (7.4%)</td><td>8.9</td><td>0.003</td></tr><tr><td> 12th grade</td><td>4,187</td><td>861 (19.6%)</td><td>3,970</td><td>516 (12.6%)</td><td>9.1</td><td>0.003</td></tr><tr><td>Race/ethnicity</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> American Indian</td><td>512</td><td>58 (9.8%)</td><td>501</td><td>38 (6.7%)</td><td>1.8</td><td>0.18</td></tr><tr><td> Asian</td><td>462</td><td>31 (5.9%)</td><td>517</td><td>33 (6.4%)</td><td>0.53</td><td>0.82</td></tr><tr><td> Black</td><td>399</td><td>39 (8.1%)</td><td>422</td><td>23 (4.7%)</td><td>2.35</td><td>0.13</td></tr><tr><td> Hispanic</td><td>2,061</td><td>146 (6.9%)</td><td>2,347</td><td>114 (4.5%)</td><td>5.43</td><td>0.02</td></tr><tr><td> Pacific Islander</td><td>415</td><td>33 (7.1%)</td><td>424</td><td>26 (5.8%)</td><td>0.32</td><td>0.57</td></tr><tr><td> White</td><td>12,724</td><td>1,657 (13.3%)</td><td>12,242</td><td>1,009 (8.5%)</td><td>11.35</td><td><0.0001</td></tr><tr><td>Substance use</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Smoked in past 30 days</td><td>823</td><td>233 (30.6%)</td><td>620</td><td>126 (19.7%)</td><td>7.53</td><td>0.006</td></tr><tr><td> Did not smoke in past 30 days</td><td>14,701</td><td>1,625 (11%)</td><td>14,533</td><td>1,029 (7.2%)</td><td>10.94</td><td>0.001</td></tr><tr><td> Drank alcohol within past 30 days</td><td>1,759</td><td>464 (26.4%)</td><td>1,387</td><td>268 (19.2%)</td><td>11.8</td><td><0.0001</td></tr><tr><td> Did not drink within the past 30 days</td><td>13,746</td><td>1,386 (10.2%)</td><td>13,704</td><td>876 (6.5%)</td><td>10.92</td><td>0.0010</td></tr><tr><td>Body weight status</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Normal weight</td><td>12,655</td><td>1,620 (12.9%)</td><td>11,255</td><td>924 (8.3%)</td><td>11.03</td><td>0.001</td></tr><tr><td> Obese (>95th percentile for weight)</td><td>1,068</td><td>55 (6.1%)</td><td>1123</td><td>60 (6.3%)</td><td>0.015</td><td>0.901</td></tr><tr><td>Parental education level</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <High school</td><td>822</td><td>81 (11.3%)</td><td>902</td><td>60 (7.5%)</td><td>2.98</td><td>0.09</td></tr><tr><td> High school graduate</td><td>2,166</td><td>311 (14.8%)</td><td>2,128</td><td>217 (10.5%)</td><td>6.17</td><td>0.01</td></tr><tr><td> Some college</td><td>2,657</td><td>370 (14%)</td><td>2,524</td><td>227 (8.4%)</td><td>7.36</td><td>0.007</td></tr><tr><td> Bachelor degree</td><td>5,781</td><td>642 (11.1%)</td><td>5,453</td><td>387 (7%)</td><td>8.73</td><td>0.003</td></tr><tr><td> Graduate degree</td><td>2,471</td><td>301 (12%)</td><td>2,457</td><td>154 (6.7%)</td><td>9.01</td><td>0.003</td></tr><tr><td>Local health district</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Bear River</td><td>1,745</td><td>198 (11.7%)</td><td>1,773</td><td>134 (7.5%)</td><td>3.34</td><td>0.07</td></tr><tr><td> Central</td><td>1,007</td><td>163 (15.9%)</td><td>964</td><td>111 (11.5%)</td><td>2.51</td><td>0.11</td></tr><tr><td> Davis</td><td>1,678</td><td>200 (13.5%)</td><td>590</td><td>51 (8.2%)</td><td>4.51</td><td>0.03</td></tr><tr><td> Salt Lake</td><td>3,984</td><td>393 (10.1%)</td><td>4,197</td><td>263 (6.6%)</td><td>7.35</td><td>0.007</td></tr><tr><td> Southeast</td><td>559</td><td>54 (8.3%)</td><td>597</td><td>57 (9.8%)</td><td>0.45</td><td>0.49</td></tr><tr><td> Southwest</td><td>1,065</td><td>156 (14%)</td><td>1,290</td><td>140 (9.7%)</td><td>2.95</td><td>0.09</td></tr><tr><td> Summit</td><td>424</td><td>50 (11.6%)</td><td>477</td><td>25 (5.3%)</td><td>4.02</td><td>0.05</td></tr><tr><td> Tooele</td><td>855</td><td>90 (10.8%)</td><td>993</td><td>74 (7.8%)</td><td>1.78</td><td>0.18</td></tr><tr><td> Tri-County</td><td>432</td><td>71 (19.7%)</td><td>433</td><td>45 (12.3%)</td><td>1.85</td><td>0.17</td></tr><tr><td> Utah County</td><td>2,177</td><td>274 (11.7%)</td><td>2,427</td><td>135 (6.7%)</td><td>5.02</td><td>0.03</td></tr><tr><td> Wasatch</td><td>321</td><td>40 (12.9%)</td><td>278</td><td>24 (9.5%)</td><td>0.58</td><td>0.44</td></tr><tr><td> Weber-Morgan</td><td>1,364</td><td>173 (14.5%)</td><td>1,206</td><td>102 (9.7%)</td><td>2.36</td><td>0.12</td></tr></table> |
23ecea3e008801c32203cb4a212688fd06dc12e309aa762282644d4903f6035d.png | complex | <table><tr><td rowspan="2">Variable</td><td>GPCP<sup>a</sup></td><td>EPG<sup>b</sup></td><td>MD<sup>c</sup></td></tr><tr><td><i>n</i> = 35</td><td><i>n</i> = 21</td><td><i>n</i> = 20</td></tr><tr><td></td><td>Median; mean (SD)</td><td>Median; mean (SD)</td><td>Median; mean (SD))</td></tr><tr><td>Age in years</td><td>86.0; 85.0 (7.5)</td><td>87.0; 84.8 (7.2)</td><td>87.5; 88.0 (5.6)</td></tr><tr><td>Baseline QoL<sup>d</sup> (EQ-5D score)</td><td>0.33; 0.38 (0.33)</td><td>0.45; 0.46 (0.26)</td><td>0.38; 0.41 (0.33)</td></tr><tr><td>Baseline functional status (Barthel Index)</td><td>57.0; 55.5 (23.3)</td><td>61.0; 59.8 (19.2)</td><td>60.5; 58.4 (20.9)</td></tr><tr><td>Baseline cognitive function (SMMSE<sup>e</sup> score)*</td><td>25.0; 23.3 (5.7)</td><td>19.5; 19.2 (5.8)</td><td>23.5; 23.4 (4.3)</td></tr><tr><td>Baseline depressive symptoms (GDS-15<sup>f</sup> score)</td><td>6.0; 5.8 (2.7)</td><td>5.0; 5.6 (2.9)</td><td>4.5; 6.0 (3.6)</td></tr><tr><td>Body mass index (BMI)<sup>g</sup></td><td>22.2; 23.6 (6.5)</td><td>24.0; 24.9 (5.3)</td><td>22.9; 23.9 (5.0)</td></tr><tr><td>Gender [n,(%) male]</td><td>15 (43)</td><td>12 (57)</td><td>5 (25)</td></tr><tr><td>n (%) who had a QoL<sup>h</sup> gain over 12 months</td><td>13 (41)</td><td>7 (41)</td><td>8 (44)</td></tr><tr><td>n (%) who had died at the end of 12 months</td><td>10 (29)</td><td>6 (29)</td><td>2 (10)</td></tr><tr><td>Place of death [n (%) in each column]</td><td></td><td></td><td></td></tr><tr><td> Hospital</td><td>6 (60)</td><td>3 (50)</td><td>1 (50)</td></tr><tr><td> Residential Care/Respite</td><td>4 (40)</td><td>3 (50)</td><td>1 (50)</td></tr><tr><td> Home/Independent living unit</td><td>0</td><td>0</td><td>0</td></tr><tr><td>When AD was completed<sup>i</sup></td><td></td><td></td><td></td></tr><tr><td> Before admission to TC<sup>j</sup></td><td>0</td><td>17 (81)</td><td>5 (25)</td></tr><tr><td> During admission to TC<sup>j</sup></td><td>35 (100)</td><td>2 (10)</td><td>15 (70)</td></tr><tr><td>Trial Arm</td><td></td><td></td><td></td></tr><tr><td> Intervention*</td><td>30 (86)</td><td>14 (67)</td><td>9 (45)</td></tr><tr><td> Usual care*</td><td>5 (14)</td><td>7 (33)</td><td>11 (55)</td></tr></table> |
c660b5c144eb34136587bf8a5ee04ebde4cc6711f467f80fc10ab5a459c16a06.png | simple | <table><tr><td></td><td>SiteLight</td><td>FINDMAP</td><td>3DEX</td><td>MIMOP</td><td>Mapitope</td><td>MIMOX</td></tr><tr><td>Coded in</td><td>C++</td><td>C++</td><td>VB</td><td>PHP</td><td>C++</td><td>Perl</td></tr><tr><td>Operating System</td><td>Linux</td><td>Not stated</td><td>Windows</td><td>Platform independent</td><td>Windows</td><td>Platform independent</td></tr><tr><td>Interface</td><td>Command Line</td><td>Not stated</td><td>Graphic</td><td>Web</td><td>Command Line</td><td>Web</td></tr><tr><td>Online Service</td><td>no</td><td>no</td><td>no</td><td>available on request</td><td>under construction</td><td>available</td></tr><tr><td>Structure Dependent</td><td>yes</td><td>no</td><td>yes</td><td>yes/no</td><td>yes</td><td>yes</td></tr></table> |
031229b26a41842f5b03065a03b3e8550b8dd36b2bdb9d4c340443550b48023e.png | simple | <table><tr><td>Rank</td><td>Suggestions for solutions to delayed diagnosis in primary care</td><td>Total priority score</td><td>Type of interventions to decrease delayed diagnosis</td><td>Breakdown points in the diagnostic process</td></tr><tr><td>1</td><td>To have more rigorous systems in place for communicating abnormal results to patients</td><td>92.3</td><td>Structured-process change</td><td>Follow-up</td></tr><tr><td>2</td><td>Direct hotlines to specialists to discuss patient problems</td><td>91.4</td><td>Structured-process change</td><td>Referral & consultation</td></tr><tr><td>3</td><td>Clear referral guidelines and pathways for other common conditions (not just cancer)</td><td>88.4</td><td>Structured-process change</td><td>Referral & consultation</td></tr><tr><td>4</td><td>Improve handovers</td><td>86.9</td><td>Structured-process change</td><td>Referral & consultation</td></tr><tr><td>6</td><td>To have “affordable” GP update courses</td><td>86.3</td><td>Educational intervention</td><td>Patient-practitioner encounter</td></tr><tr><td>5</td><td>Better training of GPs in spotting warning signs of serious conditions, diagnosis that are easily missed and safety netting</td><td>86.3</td><td>Educational intervention</td><td>Patient-practitioner encounter</td></tr><tr><td>7</td><td>Review of every delayed diagnosis to learn how, why and whether it could be prevented in the future</td><td>85.4</td><td>Additional review & education</td><td>NA</td></tr><tr><td>8</td><td>Better ways of informing patients that their results are ready and what the next best steps would be</td><td>84.8</td><td>Structured-process change</td><td>Follow-up</td></tr><tr><td>9</td><td>Training in decision making and reinforcing the concept on ongoing reflection to continuous consideration of differential diagnosis</td><td>84.5</td><td>Educational intervention</td><td>Patient-practitioner encounter</td></tr><tr><td>10</td><td>Have easier access to secondary care for the patients that GPs are worried about</td><td>83.9</td><td>Structured-process change</td><td>Referral & consultation</td></tr></table> |
3f085eb205c6094e98d377924c28f501d53e50367596f75308c96eee316e3a18.png | complex | <table><tr><td colspan="6">Neural-specific measurements: low-stability mRNAs</td></tr><tr><td>GO term</td><td>Definition</td><td><i>P</i>value</td><td>FDR</td><td>Count</td><td>Fold enrichment</td></tr><tr><td>0006351</td><td>Transcription</td><td>4 × 10<sup>−10</sup></td><td>2 × 10<sup>−7</sup></td><td>58</td><td>2.5</td></tr><tr><td></td><td><i>svp</i>, <i>dpn</i>, <i>pros</i>, <i>vvl</i>, <i>grh</i>, <i>gsb</i>, <i>onecut</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0030182</td><td>Neuron differentiation</td><td>2 × 10<sup>−7</sup></td><td>4 × 10<sup>−5</sup></td><td>48</td><td>2.3</td></tr><tr><td></td><td><i>chinmo</i>, <i>Dl</i>, <i>tup</i>, <i>Ephrin</i>, <i>Eph</i>, <i>fax</i>, <i>shot</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0007067</td><td>Mitosis</td><td>6 × 10<sup>−5</sup></td><td>3 × 10<sup>−3</sup></td><td>21</td><td>2.9</td></tr><tr><td></td><td><i>cycB3</i>, <i>cdc27</i>, <i>Sse</i>, <i>cnn</i>, <i>glu</i>, <i>mts</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0018024</td><td>Histone methyltransferase activity</td><td>2 × 10<sup>−4</sup></td><td>.02</td><td>7</td><td>6.9</td></tr><tr><td></td><td><i>G9a</i>, <i>Set1</i>, <i>Set2</i>, <i>Su(z)12</i>, <i>ash1</i>, <i>egg</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0006897</td><td>Endocytosis</td><td>4 × 10<sup>−3</sup></td><td>.08</td><td>25</td><td>1.9</td></tr><tr><td></td><td><i>Arpc4</i>, <i>shi</i>, <i>CalpA</i>, <i>pat1</i>, <i>faf</i>, <i>scb</i>, <i>Rac1</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0005840</td><td>Ribosome</td><td>2 × 10<sup>−3</sup></td><td>.06</td><td>21</td><td>2.0</td></tr><tr><td></td><td><i>RpL17</i>, <i>RpL35</i>, <i>mRpL11</i>, <i>mRpS35</i></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6">Neural-specific measurements: high-stability mRNAs</td></tr><tr><td>GO term</td><td>Definition</td><td><i>P</i>value</td><td>FDR</td><td>Count</td><td>Fold enrichment</td></tr><tr><td>0048812</td><td>Neuron projection morphogenesis</td><td>5 × 10<sup>−6</sup></td><td>6 × 10<sup>−4</sup></td><td>33</td><td>2.4</td></tr><tr><td></td><td><i>trc</i>, <i>fusl</i>, <i>Fas2</i>, <i>Appl</i>, <i>Fmr1</i>, <i>otk</i>, <i>ben</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0003924</td><td>GTPase activity</td><td>2 × 10<sup>−4</sup></td><td>.02</td><td>17</td><td>2.9</td></tr><tr><td></td><td><i>Rab23</i>, <i>Rab30</i>, <i>Rab11</i>, <i>Rho1</i>, <i>Ras64B</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0012501</td><td>Programmed cell death</td><td>2 × 10<sup>−3</sup></td><td>.06</td><td>17</td><td>2.4</td></tr><tr><td></td><td><i>grim</i>, <i>pten</i>, <i>scyl</i>, <i>egr</i>, <i>mod(mdg4)</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0004672</td><td>Protein kinase activity</td><td>9 × 10<sup>−3</sup></td><td>.24</td><td>23</td><td>1.8</td></tr><tr><td></td><td><i>CamKI</i>, <i>Cdk4</i>, <i>Ror</i>, <i>ald</i>, <i>aur</i>, <i>nmo</i>, <i>trbl</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0019226</td><td>Transmission of nerve impulse</td><td>.02</td><td>.25</td><td>17</td><td>1.8</td></tr><tr><td></td><td><i>CASK</i>, <i>CanB</i>, <i>Dap160</i>, <i>cpx</i>, <i>Sap47</i></td><td></td><td></td><td></td><td></td></tr><tr><td>0051674</td><td>Localization of cell</td><td>.01</td><td>.16</td><td>18</td><td>1.9</td></tr><tr><td></td><td><i>cbl</i>, <i>APC</i>, <i>cortactin</i>, <i>par-6</i>, <i>baz</i>, <i>spri</i></td><td></td><td></td><td></td><td></td></tr></table> |
da3b87fb1760925bc17f113b1222f74bacc4c0ab6dd88de9ef90bc02ae76f58e.png | complex | <table><tr><td> </td><td> </td><td colspan="3">Treatment</td></tr><tr><td>Variety</td><td>Tissue</td><td>Control</td><td>Mild stress</td><td>Severe stress</td></tr><tr><td>Costal</td><td>Needles</td><td>DCNC</td><td>DCNM</td><td>DCNS</td></tr><tr><td> </td><td>Wood</td><td>DCWC</td><td>DCWM</td><td>DCWS</td></tr><tr><td>Interior</td><td>Needles</td><td>DINC</td><td>DINM</td><td>DINS</td></tr><tr><td> </td><td>Wood</td><td>DIWC</td><td>DIWM</td><td>DIWS</td></tr></table> |
cce5b40676d07c42182dc5814a7e9b03d24b48bf04868b97f57dfa3b326c9708.png | simple | <table><tr><td>Type of Insurance</td><td>Estimated cases in 2005 (a)</td><td>Estimated cases in 2005 (b)</td><td>Incremental financial burden of moving from OC to LC by government (c)</td><td>Household's off-set cost from moving from OC to LC (d)</td><td>Net financial burden to society (e)</td></tr><tr><td>UC</td><td>8,000</td><td>6,400</td><td>76,800,000</td><td>32,000,000</td><td>44,800,000</td></tr><tr><td>CSMBS</td><td>2,000</td><td>1,600</td><td>19,200,000</td><td>8,000,000</td><td>11,200,000</td></tr><tr><td>Total</td><td>10,000</td><td>8,000</td><td>96,000,000</td><td>40,000,000</td><td>56,000,000</td></tr></table> |
8a9389e6930d25f4408a161348bdaca8fcc5e1e9f3550f5fc4e6e69b187f50c0.png | complex | <table><tr><td>Theme</td><td colspan="3">Balancing between ideality and reality</td></tr><tr><td>Categories</td><td>Limitation</td><td>Self-regulation</td><td>Companionship</td></tr><tr><td>Subcategories</td><td>Insufficiency</td><td>Guilt</td><td>Belonging</td></tr><tr><td></td><td>Adaptation</td><td>Motivation</td><td>Pleasure</td></tr></table> |
65770b220f4d15cb9e0025f0711edeeb46cec34e8801f9b36eb722f4892a2f1f.png | simple | <table><tr><td></td><td>A (<i>n</i>= 1930)</td><td>B (<i>n</i>= 1938)</td><td>C (<i>n</i>= 1969)</td><td>Total (<i>N</i>= 5837)</td></tr><tr><td>What would you say was the design of the study?</td><td></td><td></td><td></td><td></td></tr><tr><td>Two separate surveys of student drinking</td><td>323 (17%)</td><td>322 (17%)</td><td>290 (15%)</td><td>935 (16%)</td></tr><tr><td>Following up a group of student drinkers over time</td><td>1,523 (79%)</td><td>1,515 (78%)</td><td>1,550 (79%)</td><td>4,588 (79%)</td></tr><tr><td>Other</td><td>84 (4.4%)</td><td>101 (5.2%)</td><td>129 (6.6%)</td><td>314 (5.4%)</td></tr><tr><td>After completing the survey last month did you think more about your drinking?</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>1357 (70%)</td><td>1407 (73%)</td><td>1357 (69%)</td><td>4121 (71%)</td></tr><tr><td>Yes</td><td>455 (24%)</td><td>424 (22%)</td><td>500 (25%)</td><td>1379 (24%)</td></tr><tr><td>Don’t know</td><td>118 (6.1%)</td><td>107 (5.5%)</td><td>112 (5.7%)</td><td>337 (5.8%)</td></tr><tr><td>After completing the survey last month did you change your drinking?</td><td></td><td></td><td></td><td></td></tr><tr><td>My drinking did not change</td><td>1493 (77%)</td><td>1535 (79%)</td><td>1532 (78%)</td><td>4560 (78%)</td></tr><tr><td>My drinking decreased</td><td>358 (19%)</td><td>317 (16%)</td><td>363 (18%)</td><td>1038 (18%)</td></tr><tr><td>My drinking increased</td><td>79 (4.1%)</td><td>86 (4.4%)</td><td>74 (3.8%)</td><td>239 (4.1%)</td></tr><tr><td>Was this due to taking part in the survey? (Asked of 1038 participants who said their drinking decreased)</td><td></td><td></td><td></td><td></td></tr><tr><td>No</td><td>276 (77%)</td><td>251 (79%)</td><td>288 (79%)</td><td>815 (79%)</td></tr><tr><td>Yes</td><td>82 (23%)</td><td>66 (21%)</td><td>75 (21%)</td><td>223 (21%)</td></tr></table> |
2503a1c4249b56ea3aa7ce3d8ee58e5bc9dc1f49b9893312346a98f6aa405aa8.png | complex | <table><tr><td></td><td>Incidental PTMCs</td><td>Non-incidental PTMCs</td><td><i>P</i> value</td></tr><tr><td>Number of patients</td><td>274</td><td>61</td><td></td></tr><tr><td>Age at diagnosis</td><td>49.1 ± 12.5 (range 16 – 76) years</td><td>47.9 ± 13.1 (range 18–81) years</td><td>0.485</td></tr><tr><td rowspan="2">Gender</td><td>226F (82.5 %)</td><td>38F (62.3 %)</td><td rowspan="2"><<i>0.001</i></td></tr><tr><td>48 M (17.5 %)</td><td>23 M (37.7 %)</td></tr><tr><td>Hyperthyroidism</td><td>46/228 (20.2 %)</td><td>0/61 (0 %)</td><td><<i>0.001</i></td></tr><tr><td>Graves</td><td>21/46 (45.7 %)</td><td>0/0</td><td>–</td></tr><tr><td>Hashimoto</td><td>42/274 (15.3 %)</td><td>5/61 (8.2 %)</td><td>0.147</td></tr><tr><td>Family History</td><td>4/274 (1.5 %)</td><td>1/61 (1.6 %)</td><td>0.917</td></tr><tr><td>Singlenodular</td><td>65/274 (23.7 %)</td><td>22/61 (36.1 %)</td><td rowspan="2"><i>0.047</i></td></tr><tr><td>Multinodular</td><td>209/274 (76.3 %)</td><td>39/61 (63.9 %)</td></tr><tr><td>Unifocal</td><td>179/274 (65.3 %)</td><td>36/61 (59 %)</td><td rowspan="2">0.352</td></tr><tr><td>Multifocal</td><td>95/274 (34.7 %)</td><td>25/61 (40.1 %)</td></tr><tr><td>< or = 5 mm</td><td>96/179(53.6 %)</td><td>13/36 (36.1 %)</td><td rowspan="2">0.055</td></tr><tr><td>> 5 mm (of unifocal cases)</td><td>83/179 (46.4 %)</td><td>23/36 (63.9 %)</td></tr><tr><td>Metastases</td><td>0/274 (0 %)</td><td>0/61 (0 %)</td><td>>0.999</td></tr><tr><td>Capsule involvement</td><td>21/274 (7.7 %)</td><td>47/61 (77 %)</td><td><<i>0.001</i></td></tr><tr><td>T > 1 and/or N > 0</td><td>17/274 (6.2 %)</td><td>19/61 (31.1 %)</td><td><<i>0.001</i></td></tr><tr><td rowspan="5">Histological types</td><td>145/274 (52.9 %) CPC</td><td>25/61 (41 %)</td><td>0.091</td></tr><tr><td>53/274 (19.4 %) EFVC</td><td>8/61 (13.1 %)</td><td>0.254</td></tr><tr><td>36/274 (13.1 %) N-EFVC</td><td>22/61 (36 %)</td><td><<i>0.001</i></td></tr><tr><td>37/274 (13.5 %) SVC</td><td>4/61 (6.6 %)</td><td>0.134</td></tr><tr><td>3/274 (1.1 %) T-CVC</td><td>2/61 (3.3 %)</td><td>0.203</td></tr><tr><td>Total or near total thyroidectomy</td><td>240/274 (87.5 %)</td><td>52/61 (85.2 %)</td><td>0.620</td></tr><tr><td><sup>131</sup>I</td><td>202/274 (73.7 %)</td><td>57/61 (93.4 %)</td><td><<i>0.001</i></td></tr><tr><td>Follow up</td><td>10.9 ± 5.4 (range 5–33) years</td><td>9.1 ± 4.3 (range 5–27.5) years</td><td><i>0.005</i></td></tr><tr><td>Recurrence</td><td>2/274 (0.7 %)</td><td>0/61 (0 %)</td><td>0.503</td></tr><tr><td>Persistence</td><td>8/274 (3 %)</td><td>5/61 (8.2 %)</td><td>0.054</td></tr><tr><td>Disease free</td><td>264/274 (96.3 %)</td><td>56/61 (91.8 %)</td><td>0.120</td></tr></table> |
9948409aa706d9975d32aac37aa5df4fc96e924b83b31ea897540fabbad71550.png | simple | <table><tr><td>Hausa IPAQ-SF</td><td>Total (N = 102)</td><td>Women (n = 46)</td><td>Men (n = 56)</td></tr><tr><td></td><td>ICC (95% CI)</td><td>ICC (95% CI)</td><td>ICC (95%CI)</td></tr><tr><td>Vigorous PA (Min week<sup>-1</sup>)</td><td>0.73 (0.55-0.84)</td><td>0.44 (-0.19-0.81)</td><td>0.82 (0.67-0.91)</td></tr><tr><td>Moderate PA (Min week<sup>-1</sup>)</td><td>0.33 (0.12-0.51)</td><td>0.35 (0.05-0.59)</td><td>0.31 (0.01-0.56)</td></tr><tr><td>Walking (Min week<sup>-1</sup>)</td><td>0.56 (0.39-0.69)</td><td>0.43 (0.10-0.67)</td><td>0.63 (0.43-0.71)</td></tr><tr><td>Total PA (MET-Min week<sup>-1</sup>)</td><td>0.61 (0.47-0.72)</td><td>0.56 (0.33-0.73)</td><td>0.62 (0.43-0.76)</td></tr><tr><td>Sitting (Min week<sup>-1</sup>)</td><td>0.56 (0.43-0.68)</td><td>0.67 (0.48-0.81)</td><td>0.40 (0.15-0.60)</td></tr></table> |
4434270d84725907dcbed5df4a82d0aeeb91dbfe79eed346b971d78ad52ca041.png | complex | <table><tr><td>Item</td><td>Total case number (436)</td><td>Normal renal function group (176)</td><td>Slight decrease group (141)</td><td>Moderate and severe decrease group (119)</td></tr><tr><td>Gender (male/female) (case)</td><td>322/114</td><td>118/58</td><td>100/41</td><td>104/15</td></tr><tr><td>Age (year)</td><td>79 (60, 98)</td><td>67 (63, 85)</td><td>78 (65, 89)<sup>a</sup></td><td>81 (71, 98)<sup>bc</sup></td></tr><tr><td colspan="5"><i>Cardiac function classification (grade)</i></td></tr><tr><td> II</td><td>175 (40.1)</td><td>93 (52.8)</td><td>49 (34.8)</td><td>33 (27.7)<sup>bc</sup></td></tr><tr><td> III</td><td>141 (32.3)</td><td>62 (35.2)</td><td>43 (30.5)</td><td>36 (30.3)</td></tr><tr><td> IV</td><td>120 (27.5)</td><td>21 (11.9)</td><td>49 (34.8)<sup>b</sup></td><td>50 (42.0)<sup>bd</sup></td></tr></table> |
c598a15054c5dce006815c7889303e34e352ae79a5f89006fcf1138d58592f2c.png | simple | <table><tr><td>Factors</td><td>P</td><td>Odds</td><td>95 % CI</td></tr><tr><td>Age</td><td>0.0875</td><td>1.27742</td><td>0.96462–1.69165</td></tr><tr><td>DD</td><td>0.3805</td><td>0.9947</td><td>0.98294–1.00659</td></tr><tr><td>DAS28</td><td>0.0401</td><td>0.00284</td><td>0.00001–0.76627</td></tr><tr><td>PSL</td><td>0.3289</td><td>1.53217</td><td>0.65064–3.60805</td></tr><tr><td>MTX</td><td>0.9742</td><td>0.98265</td><td>0.34078–2.83353</td></tr><tr><td>Stage</td><td>0.8398</td><td>0.64611</td><td>0.00936–44.5802</td></tr><tr><td>Class</td><td>0.9247</td><td>1.18464</td><td>0.03524–39.8251</td></tr></table> |
69b50d17fbcb89bf8ff0df1b34e78d5346c2637bce7b7729a7d1b67abd3ad5ee.png | complex | <table><tr><td rowspan="2">Variable</td><td colspan="2">NTU<sup><i>a</i></sup></td><td colspan="2">TS<sup><i>b</i></sup></td></tr><tr><td><i>n</i><sup><i>c</i></sup></td><td>Percent (SE)</td><td><i>n</i><sup><i>c</i></sup></td><td>Percent (SE)</td></tr><tr><td>Age (years)</td></tr><tr><td>12–19</td><td>752</td><td>14.9 (0.91)</td><td>104</td><td>7.16 (0.93)</td></tr><tr><td>20–39 </td><td>563</td><td>28.9 (1.52)</td><td>205</td><td>44.4 (3.48)</td></tr><tr><td>40–59 </td><td>459</td><td>33.9 (1.56)</td><td>172</td><td>36.5 (3.32)</td></tr><tr><td>≥ 60 </td><td>522</td><td>22.2 (2.22)</td><td>89</td><td>12.0 (1.70)</td></tr><tr><td>Race/ethnicity</td></tr><tr><td>Mexican American</td><td>628</td><td>9.41 (1.25)</td><td>78</td><td>4.88 (1.20)</td></tr><tr><td>Non-Hispanic black</td><td>558</td><td>10.3 (2.01)</td><td>178</td><td>13.5 (2.24)</td></tr><tr><td>Non-Hispanic white</td><td>942</td><td>71.1 (2.92)</td><td>275</td><td>73.8 (3.35)</td></tr><tr><td>Other Hispanic or other/multi-race</td><td>168</td><td>9.18 (1.51)</td><td>39</td><td>7.83 (1.85)</td></tr><tr><td>Sex</td></tr><tr><td>Female</td><td>1,288</td><td>54.9 (0.97)</td><td>248</td><td>45.7 (2.00)</td></tr><tr><td>Male</td><td>1,008</td><td>45.1 (0.97)</td><td>322</td><td>54.3 (2.00)</td></tr><tr><td colspan="5"><sup><i>a</i></sup>Non-tobacco users (NTU): defined for this study as non-smokers with serum cotinine ≤ 10 ng/mL. <sup><i>b</i></sup>Tobacco smokers (TS): defined for this study as smokers with serum cotinine > 10 ng/mL, using cigarettes, cigars, or pipes during the last 5 days prior to physical examination. <sup><i>c</i></sup>Sample size. </td></tr></table> |
ca5c610c88e2e35de1ff2f7db2f9d4b25e873edafaa8a4a7481eb00aa383b353.png | simple | <table><tr><td></td><td><i>n</i></td><td>%</td><td>Days</td><td>IQR</td></tr><tr><td>Six-month mortality</td><td>165</td><td>35.6%</td><td></td><td></td></tr><tr><td>ICU mortality</td><td>84</td><td>17.1%</td><td></td><td></td></tr><tr><td>Hospital mortality</td><td>132</td><td>26.9%</td><td></td><td></td></tr><tr><td>Length of ventilation</td><td></td><td></td><td>11</td><td>6–20</td></tr><tr><td>ICU length of stay</td><td></td><td></td><td>13</td><td>7–23</td></tr><tr><td>Hospital length of stay</td><td></td><td></td><td>35</td><td>19–59</td></tr><tr><td>Destination after discharge</td><td></td><td></td><td></td><td></td></tr><tr><td> Home</td><td>144</td><td>40.7%</td><td></td><td></td></tr><tr><td> Other hospital</td><td>80</td><td>22.6%</td><td></td><td></td></tr><tr><td> Nursing home</td><td>76</td><td>21.5%</td><td></td><td></td></tr><tr><td> Rehabilitation unit</td><td>45</td><td>12.7%</td><td></td><td></td></tr><tr><td> Other</td><td>9</td><td>2.5%</td><td></td><td></td></tr></table> |
863ad493e6a40f6cbe1604be1128256f45cac71ddeeb302cfd188b31602b483c.png | complex | <table><tr><td>Characteristics</td><td>SLLP1-positive</td><td>SLLP1-negative</td><td>Sig.</td></tr><tr><td>Total (N = 394)</td><td>99 (25.1)</td><td>296 (74.9)</td><td></td></tr><tr><td colspan="4">Age at time of sample collection (years)</td></tr><tr><td> ≤60</td><td>64 (21.1)</td><td>240 (78.9)</td><td><i>0.001</i></td></tr><tr><td> >60</td><td>35 (38.9)</td><td>55 (61.1)</td><td></td></tr><tr><td colspan="4">BM-infiltrating plasma cells (%)</td></tr><tr><td> <10</td><td>24 (11.6)</td><td>183 (88.4)</td><td><i>0.000</i></td></tr><tr><td> 10–30</td><td>19 (33.3)</td><td>38 (66.7)</td><td></td></tr><tr><td> ≥30</td><td>37 (53.6)</td><td>32 (46.4)</td><td></td></tr><tr><td colspan="4">Serum paraprotein (g/dL)</td></tr><tr><td> <5 (IgG), <3 (IgA)</td><td>8 (14.3)</td><td>48 (85.7)</td><td>0.061</td></tr><tr><td> 5–7 (IgG), 3–5 (IgA)</td><td>7 (24.1)</td><td>22 (75.9)</td><td></td></tr><tr><td> >7 (IgG), >5 (IgA)</td><td>57 (30.0)</td><td>133 (70.0)</td><td></td></tr><tr><td colspan="4">Involved serum free light chains (mg/L)</td></tr><tr><td> ≤100</td><td>6 (30.0)</td><td>14 (70.0)</td><td>0.129</td></tr><tr><td> >100</td><td>3 (10.0)</td><td>27 (90.0)</td><td></td></tr><tr><td colspan="4">Serum albumin (g/dL)</td></tr><tr><td> ≥3.5</td><td>67 (21.8)</td><td>241 (78.2)</td><td><i>0.006</i></td></tr><tr><td> <3.5</td><td>19 (43.2)</td><td>25 (56.8)</td><td></td></tr><tr><td colspan="4">β<sub>2</sub>-microglobulin (mg/L)</td></tr><tr><td> <3.5</td><td>22 (18.6)</td><td>96 (81.4)</td><td><i>0.019</i></td></tr><tr><td> ≥3.5</td><td>18 (35.3)</td><td>33 (64.7)</td><td></td></tr><tr><td colspan="4">Serum LDH (U/L)</td></tr><tr><td> ≤300</td><td>75 (23.0)</td><td>251 (77.0)</td><td>0.082</td></tr><tr><td> >300</td><td>13 (35.1)</td><td>23 (63.9)</td><td></td></tr><tr><td colspan="4">Hemoglobin (g/dL)</td></tr><tr><td> >10.0</td><td>6 (27.3)</td><td>16 (72.7)</td><td><i>0.043</i></td></tr><tr><td> 9.9–8.5</td><td>16 (41.0)</td><td>23 (59.0)</td><td></td></tr><tr><td> <8.5</td><td>55 (22.4)</td><td>190 (77.6)</td><td></td></tr><tr><td colspan="4">Serum calcium (mmol/L)</td></tr><tr><td> ≤2.6</td><td>79 (22.8)</td><td>267 (77.2)</td><td><i>0.015</i></td></tr><tr><td> >2.6</td><td>9 (47.4)</td><td>10 (52.6)</td><td></td></tr><tr><td colspan="4">Serum creatinine (mg/dL)</td></tr><tr><td> ≤2.0</td><td>78 (22.5)</td><td>269 (77.5)</td><td><i>0.008</i></td></tr><tr><td> >2.0</td><td>9 (50.0)</td><td>9 (50.0)</td><td></td></tr><tr><td colspan="4">Treatment status</td></tr><tr><td> Untreated</td><td>25 (44.6)</td><td>31 (55.4)</td><td><i>0.003</i></td></tr><tr><td> Chemotherapy</td><td>8 (22.2)</td><td>28 (77.8)</td><td></td></tr><tr><td> AutoSCT</td><td>19 (29.2)</td><td>46 (70.8)</td><td></td></tr><tr><td> AlloSCT</td><td>47 (19.9)</td><td>189 (80.1)</td><td></td></tr></table> |
a50bb65317dcd7c9c1d8bac7cdf7d6d53e65a46cfb21cf6b819d298066bbf376.png | complex | <table><tr><td colspan="5">(a) Results from sham and temporal lobe epilepsy rats after 6 weeks of treatment with NLRP1 siRNA or control siRNA</td></tr><tr><td rowspan="2"></td><td colspan="2">Within 24 h post-stimulation</td><td colspan="2">On the 6th week post-treatment</td></tr><tr><td>Number</td><td>Rate (%)</td><td>Number</td><td>Rate (%)</td></tr><tr><td>Sham + Control siRNA</td><td>0/18</td><td>0</td><td>0/18</td><td>0</td></tr><tr><td>Sham + NLRP1 siRNA</td><td>0/18</td><td>0</td><td>0/18</td><td>0</td></tr><tr><td>TLE + Control siRNA</td><td>18/18</td><td>100</td><td>14/18</td><td>77.8</td></tr><tr><td>TLE + NLRP1 siRNA</td><td>18/18</td><td>100</td><td>8/18</td><td>44.4<sup>a</sup></td></tr><tr><td colspan="5">(b) Results from sham and TLE rats after 6 weeks of treatment with Caspase-1 siRNA or control siRNA</td></tr><tr><td>Sham + Control siRNA</td><td>0/18</td><td>0</td><td>0/18</td><td>0</td></tr><tr><td>Sham + Caspase-1 siRNA</td><td>0/18</td><td>0</td><td>0/18</td><td>0</td></tr><tr><td>TLE + Control siRNA</td><td>18/18</td><td>100</td><td>14/18</td><td>77.8</td></tr><tr><td>TLE + Caspase-1 siRNA</td><td>18/18</td><td>100<sup>b</sup></td><td>7/18</td><td>38.9<sup>b</sup></td></tr></table> |
7c1a28432b40914902803dd0bbbf2d486520185e884f3e61e12364fb4fcc9b30.png | complex | <table><tr><td></td><td colspan="2">Men</td><td colspan="2">Women</td></tr><tr><td>TUG</td><td>N (#dead)</td><td>Seconds, mean (SD)</td><td>N (#dead)</td><td>Seconds, mean (SD)</td></tr><tr><td>1 (quickest)</td><td>128 (58)</td><td>8.2 (1.0)</td><td>125 (46)</td><td>8.4 (1.2)</td></tr><tr><td>2</td><td>80 (52)</td><td>10.1 (0.3)</td><td>138 (52)</td><td>10.5 (0.5)</td></tr><tr><td>3</td><td>69 (38)</td><td>11.0 (0.4)</td><td>120 (50)</td><td>12.4 (0.6)</td></tr><tr><td>4</td><td>89 (60)</td><td>12.8 (1.2)</td><td>90 (46)</td><td>14.6 (0.7)</td></tr><tr><td>5 (slowest)</td><td>72 (53)</td><td>19.1 (10.3)</td><td>94 (51)</td><td>23.2 (12.4)</td></tr><tr><td>Total</td><td>438 (261)</td><td>11.7 (5.6)</td><td>567 (245)</td><td>13.2 (7.1)</td></tr></table> |
b9d13ff8b08fe7eff15ad33821f5f5864e6120fe6be5763a6ddea498063f096a.png | complex | <table><tr><td rowspan="2">Sensor Locations</td><td colspan="7">Year 2012</td><td colspan="2">Year 2013</td></tr><tr><td>March 19</td><td>April 23</td><td>May 30</td><td>July 26</td><td>September 7</td><td>October 19</td><td>December 19</td><td>January 23</td><td>March 10</td></tr><tr><td>1-1-1</td><td>42.4</td><td>42</td><td>40.5</td><td>39</td><td>39.1</td><td>39.5</td><td>36.6</td><td>38.9</td><td>35.2</td></tr><tr><td>1-1-2</td><td>−32.1</td><td>−29.5</td><td>−31.5</td><td>−30.4</td><td>−31.6</td><td>−31.9</td><td>−34.5</td><td>−34.3</td><td>−35</td></tr><tr><td>1-2-1</td><td>−39.1</td><td>−38.1</td><td>−38.1</td><td>−37.9</td><td>−38.1</td><td>−38.1</td><td>−38.1</td><td>−38.1</td><td>−37.9</td></tr><tr><td>1-2-2</td><td>41.5</td><td>40.7</td><td>40.7</td><td>40.4</td><td>40.7</td><td>40.7</td><td>40.7</td><td>38.9</td><td>41.6</td></tr><tr><td>1-3-1</td><td>−60.5</td><td>−67.6</td><td>−61.9</td><td>−63.9</td><td>−63.4</td><td>−67.2</td><td>−67.7</td><td>−67.4</td><td>−66.6</td></tr><tr><td>1-3-2</td><td>−38.9</td><td>−38.2</td><td>−36.4</td><td>−38.2</td><td>−38.2</td><td>−39.1</td><td>−24</td><td>−38.2</td><td>−38.4</td></tr><tr><td>1-4-1</td><td>−14.6</td><td>−14.4</td><td>−14.9</td><td>−14.7</td><td>−16.1</td><td>−16.8</td><td>−20</td><td>−17.9</td><td>−20.1</td></tr><tr><td>1-4-2</td><td>−44.5</td><td>−42.7</td><td>−43.3</td><td>−44.5</td><td>−44.6</td><td>−46.8</td><td>−48.4</td><td>−47.4</td><td>−48</td></tr><tr><td>1-5-1</td><td>−13.9</td><td>−14.3</td><td>−16.4</td><td>−16.3</td><td>−18</td><td>−17.7</td><td>−19.9</td><td>−17.9</td><td>−22.2</td></tr><tr><td>1-5-2</td><td>15.9</td><td>17</td><td>15.1</td><td>14.7</td><td>14.7</td><td>13.2</td><td>9.1</td><td>15.2</td><td>11.5</td></tr><tr><td>1-6-1</td><td>−81.2</td><td>−79.4</td><td>−80.5</td><td>−81.8</td><td>−81.9</td><td>−83.7</td><td>−85</td><td>−82.4</td><td>−82.5</td></tr><tr><td>1-6-2</td><td>−57.3</td><td>−55.8</td><td>−57.6</td><td>−57.1</td><td>−59</td><td>−60.4</td><td>−61.2</td><td>−61.3</td><td>−63.2</td></tr></table> |
84610d8a1f5f6dc8199a8abc17e5c702b34791e5090c618925c7548d70e03942.png | simple | <table><tr><td>Concentration mIU/ml</td><td>Vaccination protection</td><td>Vaccination recommendation</td><td>Before vaccination</td><td>After vaccination</td></tr><tr><td><= 30</td><td>No</td><td>Basic immunization</td><td>0</td><td>0</td></tr><tr><td>]30 – 100]</td><td>Not surely guaranteed</td><td>Booster vaccination</td><td>8</td><td>0</td></tr><tr><td>]100 – 500]</td><td>Existent</td><td>Booster vaccination</td><td>29</td><td>2</td></tr><tr><td>]500 – 1000]</td><td>Sufficient</td><td>Control in 2 years</td><td>13</td><td>4</td></tr><tr><td>]1000 – 5000]</td><td>Long term</td><td>Control in 5–10 years</td><td>41</td><td>6</td></tr><tr><td>> 5000</td><td>Extremely high</td><td>Control in 10 years</td><td>9</td><td>79</td></tr></table> |
db86d1d7645cbf0a1b7607e0d2a0babca8bdd6f5e0c09f6f46b3bd8016984e4a.png | simple | <table><tr><td></td><td><i>Oocyte</i></td><td><i>1-cell</i></td><td><i>2-cell</i></td><td><i>4-cell</i></td><td><i>8-cell</i></td><td><i>Morula</i></td><td><i>ICM</i></td><td><i>TE</i></td></tr><tr><td>Mouse embryos*</td><td>14 h</td><td>24–26 h</td><td>36 h</td><td>48 h</td><td>60 h</td><td>72 h</td><td>96 h</td><td>96 h</td></tr><tr><td>Pig <i>in vivo</i> embryos**</td><td>24 h after estrus</td><td>24 h</td><td>40–45 h</td><td>65–72 h</td><td>84–90 h</td><td>108–115 h</td><td>156–160 h</td><td>156–160 h</td></tr><tr><td>Pig SCNT embryos***</td><td><i>In vitro</i> matured</td><td>24 h</td><td>40 h</td><td>65–72 h</td><td>84–90 h</td><td>108–115 h</td><td>156–160 h</td><td>156–160 h</td></tr></table> |
f6b3e8c30ee694665e4f0d2576f21e233e9fde0d1951757301f97287f6d8b079.png | complex | <table><tr><td rowspan="2">Condition</td><td colspan="2">Experiment 1</td><td colspan="2">Experiment 2</td></tr><tr><td>93 Hz</td><td>109 Hz</td><td>217 Hz</td><td>233 Hz</td></tr><tr><td>Attend-Low</td><td>4.7 ± 1.6</td><td>4.8 ± 1.8</td><td>6.2 ± 1.8</td><td>6.4 ± 2.1</td></tr><tr><td>Attend-High</td><td>4.4 ± 2.2</td><td>5.2 ± 1.5</td><td>6.0 ± 2.0</td><td>6.5 ± 2.5</td></tr><tr><td>Attend-Visual (low stream first)</td><td>4.1 ± 2.4</td><td>5.6 ± 2.2</td><td>6.1 ± 2.1</td><td>7.1 ± 2.8</td></tr><tr><td>Attend-Visual (high stream first)</td><td>5.5 ± 3.1</td><td>4.9 ± 1.8</td><td>5.7 ± 3.3</td><td>7.1 ± 3.2</td></tr></table> |
7f207ac9526744b1581faa7d46556edb7f889b653da44d3e97ec2f2f7585d174.png | complex | <table><tr><td>Mod.</td><td>Mol. exp.</td><td>wt (<i>CEN</i> vec)</td><td><i>trm82∆</i> (<i>CEN TRM82</i>)</td><td><i>trm82∆</i> (<i>CEN</i> vec)</td><td><i>trm82∆</i> (<i>CEN trm82-K223L</i>)</td><td><i>trm82∆</i> (<i>CEN trm82-K223R</i>)</td></tr><tr><td colspan="7">30 °C</td></tr><tr><td>m<sup>7</sup>G</td><td>1</td><td>0.41 ± 0.04</td><td>0.34 ± 0.03</td><td><0.03</td><td>0.21 ± 0.01</td><td>0.32 ± 0.04</td></tr><tr><td>Ψ</td><td>2</td><td>2.09 ± 0.06</td><td>1.94 ± 0.03</td><td>1.85 ± 0.04</td><td>1.99 ± 0.07</td><td>2.06 ± 0.05</td></tr><tr><td>Cm</td><td>1</td><td>0.89 ± 0.09</td><td>0.92 ± 0.05</td><td>0.93 ± 0.08</td><td>0.95 ± 0.03</td><td>0.93 ± 0.06</td></tr><tr><td>Gm</td><td>1</td><td>0.72 ± 0.01</td><td>0.76 ± 0.07</td><td>0.76 ± 0.03</td><td>0.73 ± 0.08</td><td>0.75 ± 0.02</td></tr><tr><td>m<sup>5</sup>C</td><td>2</td><td>1.53 ± 0.06</td><td>1.64 ± 0.07</td><td>1.69 ± 0.03</td><td>1.66 ± 0.06</td><td>1.59 ± 0.03</td></tr><tr><td>m<sup>2</sup>G</td><td>1</td><td>0.78 ± 0.02</td><td>0.83 ± 0.04</td><td>0.87 ± 0.02</td><td>0.83 ± 0.04</td><td>0.82 ± 0.03</td></tr><tr><td colspan="7">37 °C</td></tr><tr><td>m<sup>7</sup>G</td><td>1</td><td>0.37 ± 0.03</td><td>0.21 ± 0.03</td><td><0.03</td><td><0.03</td><td>0.18 ± 0.02</td></tr><tr><td>Ψ</td><td>2</td><td>2.00 ± 0.08</td><td>1.91 ± 0.06</td><td>1.87 ± 0.01</td><td>1.82 ± 0.10</td><td>1.92 ± 0.01</td></tr><tr><td>Cm</td><td>1</td><td>0.98 ± 0.08</td><td>1.00 ± 0.14</td><td>0.91 ± 0.02</td><td>0.93 ± 0.05</td><td>0.90 ± 0.04</td></tr><tr><td>Gm</td><td>1</td><td>0.77 ± 0.03</td><td>0.84 ± 0.02</td><td>0.91 ± 0.05</td><td>0.96 ± 0.02</td><td>0.84 ± 0.02</td></tr><tr><td>m<sup>5</sup>C</td><td>2</td><td>1.63 ± 0.03</td><td>1.69 ± 0.02</td><td>1.79 ± 0.05</td><td>1.76 ± 0.04</td><td>1.71 ± 0.02</td></tr><tr><td>m<sup>2</sup>G</td><td>1</td><td>0.82 ± 0.05</td><td>0.88 ± 0.02</td><td>0.90 ± 0.07</td><td>0.94 ± 0.06</td><td>0.86 ± 0.02</td></tr></table> |
07b63e186416917487c8bcdc874b4119cb0d87effa65c4f83d3f3b6a796d9ac5.png | simple | <table><tr><td>Period</td><td>Total biopsies (n)</td><td>Adequate biopsies (n,%)</td><td>Suboptimal biopsies (n,%)</td><td>Inadequate biopsies (n,%)</td><td>Difference in adequacy (%)*</td><td>p value</td></tr><tr><td>1</td><td>127</td><td>40 (31%)</td><td>43 (34%)</td><td>44 (35%)</td><td>NA</td><td>NA</td></tr><tr><td>2</td><td>432</td><td>311 (72%)</td><td>54 (13%)</td><td>67 (16%)</td><td>+40% (31, 50)</td><td>< 0.0001</td></tr><tr><td>3</td><td>104</td><td>94 (90%)</td><td>2 (2%)</td><td>8 (8%)</td><td>+18% (8, 29)</td><td><0.0001</td></tr></table> |
7cb9a56563c21910dde4f194dd923b8c12b28b384f6ef0791fdf90a9186949b8.png | complex | <table><tr><td rowspan="3">Input layer</td><td colspan="5">Hidden layer</td></tr><tr><td>Neuron 1</td><td>Neuron 2</td><td>Neuron 3</td><td>Neuron 4</td><td>Neuron 5</td></tr><tr><td>Bias</td><td>−0.756</td><td>−0.715</td><td>−0.521</td><td>1.154</td><td>−1.304</td></tr><tr><td>Awareness</td><td>−0.184</td><td>0.403</td><td>0.548</td><td>−0.239</td><td>0.427</td></tr><tr><td>Knowledge</td><td>−0.489</td><td>0.276</td><td>−0.009</td><td>0.063</td><td>0.107</td></tr><tr><td>Skill</td><td>0.394</td><td>−0.090</td><td>0.420</td><td>−0.561</td><td>0.332</td></tr><tr><td>Attitude</td><td>−0.554</td><td>0.374</td><td>0.312</td><td>−0.060</td><td>0.151</td></tr><tr><td>Social capital</td><td>0.017</td><td>0.801</td><td>0.392</td><td>−0.718</td><td>0.558</td></tr><tr><td>Damage severity</td><td>−0.258</td><td>−0.194</td><td>0.080</td><td>−0.063</td><td>0.467</td></tr><tr><td>Recovery capacity</td><td>0.287</td><td>0.286</td><td>0.280</td><td>−0.354</td><td>−0.185</td></tr><tr><td>Employment recovery</td><td>−0.519</td><td>−0.173</td><td>0.139</td><td>0.217</td><td>0.407</td></tr></table> |
e3b0c4ee37631994979a8bc60abc4605e22619caa957bfc8d17016586b6d2bdc.png | complex | <table><tr><td>Lakes</td><td>Metals</td><td>Pb</td><td>Cd</td><td>Cu</td><td>Fe</td><td>Mn</td></tr><tr><td rowspan="2">Futala</td><td>BII</td><td>0.14 ± 0.24</td><td>0.09 ± 0.33</td><td>0.08 ± 0.83</td><td>49.0 ± 0.33</td><td>1.23 ± 0.49</td></tr><tr><td>AII</td><td>0.32 ± 0.89</td><td>0.33 ± 0.58</td><td>4.40 ± 0.72</td><td>169.1 ± 0.82</td><td>2.60 ± 0.67</td></tr><tr><td rowspan="2">Gandhi Sagar</td><td>BII</td><td>0.19 ± 0.29</td><td>0.14 ± 0.51</td><td>1.23 ± 0.42</td><td>52.5 ± 0.37</td><td>2.15 ± 0.23</td></tr><tr><td>AII</td><td>0.83 ± 0.76</td><td>0.47 ± 0.80</td><td>5.10 ± 0.67</td><td>189.3 ± 0.61</td><td>3.60 ± 0.77</td></tr><tr><td rowspan="2">Ambazari</td><td>BII</td><td>0.15 ± 0.20</td><td>0.13 ± 0.62</td><td>1.70 ± 0.75</td><td>63.2 ± 0.50</td><td>1.10 ± 0.59</td></tr><tr><td>AII</td><td>0.56 ± 0.34</td><td>0.25 ± 0.28</td><td>3.60 ± 0.58</td><td>177.9 ± 0.10</td><td>2.90 ± 0.94</td></tr><tr><td>PL**</td><td>-</td><td>0.214</td><td>0.1</td><td>3.0</td><td>43.0</td><td>2.0-9.0</td></tr></table> |
788d4d3d3a45c2bbea1b28286fdddc2fe8b81cc69ae16b0f8420b76d0ebd8a43.png | complex | <table><tr><td>Variables</td><td colspan="2">Recurrence free survival</td><td><i>P</i></td></tr><tr><td> </td><td>RR</td><td>95% CI</td><td> </td></tr><tr><td>Ulinastatin administration</td><td>0.149</td><td>0.063-0.351</td><td><0.05</td></tr><tr><td>TNM</td><td>1.812</td><td>0.652-5.038</td><td>0.254</td></tr><tr><td>Alcohol consumption</td><td>2.066</td><td>0.909-4.344</td><td>0.757</td></tr><tr><td>Smoking</td><td>1.088</td><td>0.534-2.217</td><td>0.817</td></tr><tr><td>Gender</td><td>0.916</td><td>0.425-1.973</td><td>0.822</td></tr></table> |
467f1a58ec41d1bc85789a0bea66abfd5b535ce2e2a8bdb1f5d328a7b91f1463.png | complex | <table><tr><td></td><td colspan="7">Urine iodine levels <i>n</i> (%)</td></tr><tr><td><i>Age group (yrs)</i></td><td><i><20</i></td><td><i>20–49</i></td><td><i>50–149</i></td><td><i>150–249</i></td><td><i>250–499</i></td><td><i>500</i></td><td><i>Total</i></td></tr><tr><td> <20</td><td>2 (16.67)</td><td>2 (16.67)</td><td>3 (25.00)</td><td>1 (8.33)</td><td>2 (16.67)</td><td>2 (16.67)</td><td>12</td></tr><tr><td> 20–24</td><td>4 (13.33)</td><td>2 (6.67)</td><td>5 (16.67)</td><td>4 (13.33)</td><td>9 (30.00)</td><td>6 (20.00)</td><td>30</td></tr><tr><td> 25–29</td><td>2 (5.71)</td><td>2 (5.71)</td><td>8 (22.86)</td><td>2 (5.71)</td><td>7 (20.00)</td><td>14 (40.00)</td><td>35</td></tr><tr><td> 30–34</td><td>3 (12.50)</td><td>3 (12.50)</td><td>7 (29.17)</td><td>6 (25.00)</td><td>1 (4.17)</td><td>4 (16.67)</td><td>24</td></tr><tr><td> 35–39</td><td>2 (11.76)</td><td>3 (17.65)</td><td>1 (5.88)</td><td>2 (11.76)</td><td>2 (11.76)</td><td>7 (41.18)</td><td>17</td></tr><tr><td> ≥40</td><td>1 (50.00)</td><td>0 (0.00)</td><td>1 (50.00)</td><td>0 (0.00)</td><td>0 (0.00)</td><td>0 (0.00)</td><td>2</td></tr><tr><td><i>Occupation</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Formal</td><td>0 (0)</td><td>0 (0)</td><td>1 (16.67)</td><td>1 (16.67)</td><td>1 (16.67)</td><td>3 (50)</td><td>6</td></tr><tr><td> Non-formal</td><td>11 (12.36)</td><td>9 (10.11)</td><td>19 (21.35)</td><td>11 (12.36)</td><td>15 (16.85)</td><td>24 (26.97)</td><td>89</td></tr><tr><td> None</td><td>3 (12.00)</td><td>3 (12.00)</td><td>5 (20.00)</td><td>3 (12.00)</td><td>5 (20.00)</td><td>6 (24.00)</td><td>25</td></tr><tr><td><i>Trimester</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> First</td><td>2 (7.14)</td><td>4 (14.29)</td><td>8 (28.57)</td><td>2 (7.14)</td><td>5 (17.86)</td><td>7 (25.00)</td><td>28</td></tr><tr><td> Second</td><td>7 (11.48)</td><td>6 (9.84)</td><td>11 (18.03)</td><td>5 (8.20)</td><td>12 (19.97)</td><td>20 (32.79)</td><td>61</td></tr><tr><td> Third</td><td>5 (16.13)</td><td>2 (6.45)</td><td>6 (19.35)</td><td>8 (25.81)</td><td>4 (12.90)</td><td>6 (19.35)</td><td>31</td></tr><tr><td><i>Use of iodated salt</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Yes</td><td>0 (0.00)</td><td>0 (0.00)</td><td>13 (16.25)</td><td>14 (17.50)</td><td>20 (25.00)</td><td>33 (41.25)</td><td>0</td></tr><tr><td> No</td><td>14 (35.00)</td><td>12 (30.00)</td><td>12 (30.00)</td><td>1 (2.50)</td><td>1 (2.50)</td><td>0 (0.00)</td><td>0</td></tr></table> |
bdc572304c483ed3fb0d41ec66e22346addb23d985d257207b62f9edb59a8aa5.png | simple | <table><tr><td>Calculation (cm<sup>−1</sup>)</td><td>Solid (cm<sup>−1</sup>)</td><td>SERS-Ag (cm<sup>−1</sup>)</td><td>SERS-Au (cm<sup>−1</sup>)</td><td>Assignments</td></tr><tr><td>606 (w)</td><td>615 (w)</td><td>626 (w)</td><td>626 (w)</td><td>δ(C–C–C)ip δ(S–C–N)ip</td></tr><tr><td>748 (m)</td><td>778 (m)</td><td>782 (vs)</td><td>783 (m)</td><td>δ(C–H)oop</td></tr><tr><td>957 (w)</td><td>985 (w)</td><td>988 (m)</td><td>-</td><td>υ(C–S)</td></tr><tr><td>1000 (m)</td><td>1010 (m)</td><td>1007 (vs)</td><td>1007 (s)</td><td>δ(C–H)ip</td></tr><tr><td>1139 (w)</td><td>1118 (w)</td><td>1116 (w)</td><td>1116 (w)</td><td>δ(C–H)ip</td></tr><tr><td>1158 (m)</td><td>1154 (w)</td><td>1147 (m)</td><td>1147 (w)</td><td>δ(C–H)ip</td></tr><tr><td>1215 (w)</td><td>1255 (m)</td><td>1239 (w)</td><td>-</td><td>υ ring</td></tr><tr><td>1270 (s)</td><td>1277 (s)</td><td>1279 (m)</td><td>1270 (m)</td><td>υ ring + δ(C–H)ip</td></tr><tr><td>1313 (w)</td><td>1303 (w)</td><td>1322 (m)</td><td>1326 (m)</td><td>δ(C–H)ip</td></tr><tr><td>1401 (w)</td><td>1403 (w)</td><td>1404 (m)</td><td>1406 (m)</td><td>υ(C=C)</td></tr><tr><td>1445 (s)</td><td>1456 (s)</td><td>1433 (w)</td><td>1462 (m)</td><td>υ(C=N)</td></tr><tr><td>1498 (w)</td><td>1492 (w)</td><td>1492 (w)</td><td>1493 (w)</td><td>υ(C=C) + δ(N–H)ip</td></tr><tr><td>1579 (vs)</td><td>1577 (vs)</td><td>1576 (s)</td><td>1586 (s)</td><td>υ(C=N)</td></tr><tr><td>1599 (s)</td><td>1591 (s)</td><td>-</td><td>-</td><td>υ(C=N)</td></tr><tr><td>1641 (w)</td><td>1623 (w)</td><td>1621 (w)</td><td>1626 (w)</td><td>υ(C=N)</td></tr></table> |
3b7108eb382d654d38b913f92d8229fa4a77ce15844f9bb589411334949375ae.png | simple | <table><tr><td>Genotype</td><td>GeneID</td><td>log2 ratio</td><td>P-value</td><td>q-value</td><td>Gene description</td></tr><tr><td>R2</td><td>Comp133037_c0</td><td>7.0454</td><td>1.82E-08</td><td>4.59E-07</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. japonica GN = DREB1A PE = 2 SV = 1</td></tr><tr><td></td><td>Comp143318_c0</td><td>7.4867</td><td>3.61E-38</td><td>3.66E-36</td><td>Dehydration-responsive element-binding protein 1H OS = Oryza sativa subsp. japonica GN = DREB1H PE = 3 SV = 1</td></tr><tr><td></td><td>Comp155879_c0</td><td>5.8445</td><td>0</td><td>0</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1</td></tr><tr><td>R3</td><td>Comp133037_c0</td><td>5.9961</td><td>1.46E-05</td><td>0.0003279</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. japonica GN = DREB1A PE = 2 SV = 1</td></tr><tr><td></td><td>Comp143318_c0</td><td>5.5908</td><td>4.28E-14</td><td>2.24E-12</td><td>Dehydration-responsive element-binding protein 1H OS = Oryza sativa subsp. japonica GN = DREB1H PE = 3 SV = 1</td></tr><tr><td></td><td>Comp155879_c0</td><td>4.8139</td><td>2.87E-206</td><td>2.62E-203</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1</td></tr><tr><td>R4</td><td>Comp159413_c1</td><td>4.2154</td><td>1.47E-06</td><td>5.96E-05</td><td>Dehydration-responsive element-binding protein 1C OS = Oryza sativa subsp. japonica GN = DREB1C PE = 2 SV = 1</td></tr><tr><td>S1</td><td>Comp155879_c0</td><td>3.1428</td><td>2.83E-08</td><td>1.24E-06</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1</td></tr><tr><td>S3</td><td>Comp143318_c0</td><td>8.4116</td><td>4.08E-05</td><td>0.0014065</td><td>Dehydration-responsive element-binding protein 1H OS = Oryza sativa subsp. japonica GN = DREB1H PE = 3 SV = 1</td></tr><tr><td></td><td>Comp155879_c0</td><td>5.2997</td><td>1.58E-66</td><td>1.62E-63</td><td>Dehydration-responsive element-binding protein 1A OS = Oryza sativa subsp. indica GN = DREB1A PE = 3 SV = 1</td></tr><tr><td></td><td>Comp159413_c1</td><td>3.2936</td><td>0.0001694</td><td>0.0049795</td><td>Dehydration-responsive element-binding protein 1C OS = Oryza sativa subsp. japonica GN = DREB1C PE = 2 SV = 1</td></tr></table> |
61e797e1e02333b5ba41902c3e5bc355f2e3a69c0f3cd45b846b526d5d4c5fbd.png | complex | <table><tr><td colspan="2"></td><td colspan="2">Complete data<i>N</i> = 11,920</td><td colspan="2">Missing data<i>N</i> = 879</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>Mean (SE)</td><td>27.8</td><td>(0.10)</td><td>28.4</td><td>(0.28)</td></tr><tr><td>Age (y)</td><td>Mean (SE)</td><td>46.2</td><td>(0.28)</td><td>47.8</td><td>(1.2)</td></tr><tr><td>Sex</td><td>(% male)</td><td>46.4%</td><td></td><td>43.1%</td><td></td></tr><tr><td>Diabetes</td><td>(%)</td><td>10.1%</td><td></td><td>11.5%</td><td></td></tr><tr><td rowspan="6">Poverty index</td><td>(%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Poor</td><td>15.4%</td><td></td><td>15.2%</td><td></td></tr><tr><td>Near poor</td><td>5.6%</td><td></td><td>9.1%</td><td></td></tr><tr><td>Low income</td><td>14.8%</td><td></td><td>17.5%</td><td></td></tr><tr><td>Middle income</td><td>29.7%</td><td></td><td>33.2%</td><td></td></tr><tr><td>High income</td><td>33.1%</td><td></td><td>25.0%</td><td></td></tr><tr><td rowspan="6">Race</td><td>(%)</td><td></td><td></td><td></td><td></td></tr><tr><td>Hispanic</td><td>17.3%</td><td></td><td>21.4%</td><td></td></tr><tr><td>White</td><td>62.5%</td><td></td><td>59.2%</td><td></td></tr><tr><td>Black</td><td>12.1%</td><td></td><td>13.1%</td><td></td></tr><tr><td>Asian</td><td>5.3%</td><td></td><td>4.4%</td><td></td></tr><tr><td>Other or multiple</td><td>2.9%</td><td></td><td>1.9%</td><td></td></tr></table> |
6969343b70575c1ff221b1b1fee3fb85d74fdf4cdf659ef24ff7a57bcef6450d.png | simple | <table><tr><td>Analysis*</td><td>Left ventricular mass (SD) in grams while on CHD</td><td>Left ventricular mass (SD) in grams after conversion to INHD</td><td>Change in LVM (SD) in grams</td><td>p-value</td></tr><tr><td>Primary (n = 37)</td><td>219 ± 66</td><td>186 ± 69</td><td>-32 ± 58</td><td>0.002</td></tr><tr><td>Secondary (n = 31)</td><td>215 ± 71</td><td>174 ± 62</td><td>-40 ± 56</td><td>0.0004</td></tr></table> |
1c64ae5e1a40d8e9cbbdbf29ae8113ff45828dedf1cb655b477218b99ab4e2ae.png | complex | <table><tr><td>Participants’ Smoking and Vaping Use at Time of Interview</td><td>Daily</td><td>Weekly</td><td>Monthly</td><td>Total No. of Participants</td></tr><tr><td>Dual users</td><td></td><td></td><td></td><td></td></tr><tr><td>Smoking status</td><td>5</td><td>4</td><td>0</td><td rowspan="2">9</td></tr><tr><td>Vaping status</td><td>3</td><td>5</td><td>1</td></tr><tr><td>Smokers</td><td></td><td></td><td></td><td></td></tr><tr><td>Smoking status</td><td>9</td><td>0</td><td>0</td><td>9</td></tr><tr><td>Vapers</td><td></td><td></td><td></td><td></td></tr><tr><td>Vaping status</td><td>6</td><td>1</td><td>0</td><td>7</td></tr></table> |
f38b39411a81344573d005a0009b581270477fe4cb7ae6e6f3999e31968004f0.png | complex | <table><tr><td></td><td>No treatment intensification</td><td>Treatment intensification</td></tr><tr><td>Age, years, mean (SD)</td><td>52.6 (12.6)</td><td>51.0 (12.4)</td></tr><tr><td>Sex, <i>n</i> (% female)</td><td>46 (78.9)</td><td>39 (68.4)</td></tr><tr><td colspan="3">Treatment arm</td></tr><tr><td> Early remission</td><td>46.2</td><td>57.2</td></tr><tr><td> MTX + SSZ + HCQ + prednisone</td><td>20.9</td><td>19.9</td></tr><tr><td> MTX + adalimumab</td><td>19.1</td><td>16.0</td></tr><tr><td> Out of protocol</td><td>13.8</td><td>6.7</td></tr><tr><td>Symptom duration, weeks, median (IQR)</td><td>20 (9–35)</td><td>19 (9–32)</td></tr><tr><td>Diagnosed RA, % meeting 2010 ACR/EULAR criteria</td><td>46 (79.2)</td><td>47 (84.5)</td></tr><tr><td>Anti-citrullinated protein antibodies, % positive</td><td>34 (57.6)</td><td>35 (61.9)</td></tr><tr><td>Rheumatoid factor, % positive</td><td>33 (58.9)</td><td>34 (63.0)</td></tr><tr><td>Health Assessment Questionnaire (0–3)<sup>a</sup>, mean (SD)</td><td>0.78 (0.56)</td><td>0.63 (0.48)</td></tr><tr><td>Disease Activity Score, mean (SD)</td><td>1.95 (0.23)</td><td>1.99 (0.23)</td></tr><tr><td>Tender joint count, median (IQR)</td><td>2 (2–4)</td><td>3 (2–4)</td></tr><tr><td>Swollen joint count, median (IQR)</td><td>0 (0–1)</td><td>1 (0–2)</td></tr><tr><td>VAS general health (0–100)<sup>b</sup>, mean (SD)</td><td>31.0 (19.6)</td><td>31.7 (20.3)</td></tr><tr><td>Erythrocyte sedimentation rate, mm/h, median (IQR)</td><td>15.7 (13.0)</td><td>13.9 (11.2)</td></tr></table> |
1a20120cb8c17190e7e24c191b7e87d3d915ec96579d8c86d06bcf6d3528e329.png | simple | <table><tr><td>Zn</td><td>Supplemented</td><td>Analyzed Zn</td></tr><tr><td>source</td><td>Zn (mg/kg)</td><td>content (mg/kg)<sup>a</sup></td></tr><tr><td>Basal diet</td><td>0</td><td>25.00</td></tr><tr><td>ZnO</td><td>8</td><td>39.18</td></tr><tr><td>Bioplex Zn</td><td>8</td><td>32.64</td></tr><tr><td>ZnO</td><td>40</td><td>68.46</td></tr><tr><td>Bioplex Zn</td><td>40</td><td>70.29</td></tr></table> |
262721d03e0847c12b8ee8581601aeacd92e4f25f45e110982a640c6e4933bb3.png | complex | <table><tr><td></td><td colspan="5">Fifths of observed vegetable intake</td><td></td></tr><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td><i>p</i>‐trendb</td></tr><tr><td>Total vegetables, g/day</td><td>≤ 82.8</td><td>>82.8 to ≤ 126.4</td><td>>126.4 to ≤ 182.1</td><td>>182.1 to ≤ 281.6</td><td>>281.7</td><td></td></tr><tr><td>Cases, <i>n</i></td><td>1,526</td><td>1,451</td><td>1,457</td><td>1,549</td><td>1,053</td><td></td></tr><tr><td>HR (95% CI)</td><td>1 ref</td><td>1.04 (0.96–1.12)</td><td>1.01 (0.93–1.09)</td><td>1.07 (0.99–1.16)</td><td>1.04 (0.95–1.14)</td><td>0.4</td></tr><tr><td>Adjusted HR (95% CI)a</td><td>1 ref</td><td>1.03 (0.96–1.11)</td><td>0.99 (0.92–1.07)</td><td>1.05 (0.97–1.14)</td><td>1.02 (0.93–1.12)</td><td>0.6</td></tr><tr><td>Cruciferous vegetables, g/day</td><td>≤ 3.0</td><td>>3.0 to ≤ 9.2</td><td>>9.2 to ≤ 18.7</td><td>>18.7 to ≤ 36.6</td><td>>36.6</td><td></td></tr><tr><td>Cases, <i>n</i></td><td>1,457</td><td>1,287</td><td>1,253</td><td>1,190</td><td>1,207</td><td></td></tr><tr><td>HR (95% CI)</td><td>1 ref</td><td>1.06 (0.97–1.15)</td><td>1.05 (0.96–1.15)</td><td>1.07 (0.98–1.16)</td><td>1.06 (0.96–1.18)</td><td>0.4</td></tr><tr><td>Adjusted HR (95% CI)a</td><td>1 ref</td><td>1.06 (0.97–1.15)</td><td>1.04 (0.95–1.13)</td><td>1.05 (0.96–1.15)</td><td>1.06 (0.96–1.17)</td><td>0.5</td></tr><tr><td>Leafy vegetables, g/day</td><td>≤ 1.6</td><td>>1.6 to ≤ 6.0</td><td>>6.0 to ≤ 15.1</td><td>>15.1 to ≤ 36.9</td><td>>36.9</td><td></td></tr><tr><td>Cases, <i>n</i></td><td>1,773</td><td>1,453</td><td>1,218</td><td>1,034</td><td>916</td><td></td></tr><tr><td>HR (95% CI)</td><td>1 ref</td><td>1.03 (0.96–1.11)</td><td>1.09 (1.00–1.18)</td><td>1.04 (0.95–1.14)</td><td>1.09 (0.97–1.22)</td><td>0.3</td></tr><tr><td>Adjusted HR (95% CI)a</td><td>1 ref</td><td>1.01 (0.94–1.09)</td><td>1.06 (0.97–1.16)</td><td>1.01 (0.92–1.11)</td><td>1.06 (0.95–1.19)</td><td>0.4</td></tr><tr><td>Fruiting vegetables, g/day</td><td>≤ 21.6</td><td>>21.6 to ≤ 36.5</td><td>>36.5 to ≤ 56.3</td><td>>56.3 to ≤ 97.8</td><td>>97.8</td><td></td></tr><tr><td>Cases, <i>n</i></td><td>1,642</td><td>1,590</td><td>1,465</td><td>1,365</td><td>974</td><td></td></tr><tr><td>HR (95% CI)</td><td>1 ref</td><td>1.07 (1.00–1.15)</td><td>1.05 (0.97–1.13)</td><td>1.03 (0.95–1.11)</td><td>1.04 (0.95–1.14)</td><td>0.8</td></tr><tr><td>Adjusted HR (95% CI)a</td><td>1 ref</td><td>1.06 (0.99–1.14)</td><td>1.04 (0.96–1.12)</td><td>1.01 (0.94–1.10)</td><td>1.03 (0.94–1.13)</td><td>0.9</td></tr><tr><td>Tomatoes, g/day</td><td>≤ 9.0</td><td>>9.0 to ≤ 18.9</td><td>>18.9 to ≤ 30.8</td><td>>30.8 to ≤ 67.3</td><td>>67.3</td><td></td></tr><tr><td>Cases, <i>n</i></td><td>1,612</td><td>1,540</td><td>1,443</td><td>1,480</td><td>961</td><td></td></tr><tr><td>HR (95% CI)</td><td>1 ref</td><td>1.05 (0.97–1.13)</td><td>1.04 (0.96–1.12)</td><td>1.01 (0.93–1.09)</td><td>1.09 (0.98–1.21)</td><td>0.2</td></tr><tr><td>Adjusted HR (95% CI)a</td><td>1 ref</td><td>1.04 (0.97–1.12)</td><td>1.03 (0.95–1.11)</td><td>1.00 (0.92–1.08)</td><td>1.08 (0.97–1.20)</td><td>0.2</td></tr><tr><td>Root vegetables, g/day</td><td>≤ 3.8</td><td>>3.8 to ≤ 8.9</td><td>>8.9 to ≤ 16.3</td><td>>16.3 to ≤ 35.5</td><td>>35.5</td><td></td></tr><tr><td>Cases, <i>n</i></td><td>1,416</td><td>1,371</td><td>1,353</td><td>1,334</td><td>1,562</td><td></td></tr><tr><td>HR (95% CI)</td><td>1 ref</td><td>1.01 (0.93–1.09)</td><td>1.02 (0.94–1.10)</td><td>1.01 (0.93–1.09)</td><td>1.04 (0.96–1.13)</td><td>0.3</td></tr><tr><td>Adjusted HR (95% CI)a</td><td>1 ref</td><td>1.00 (0.92–1.08)</td><td>1.00 (0.92–1.08)</td><td>0.99 (0.92–1.07)</td><td>1.02 (0.94–1.11)</td><td>0.5</td></tr></table> |
06266bc210d3ed9f03982b1082ed027c6caf8518bf5f30851d755d920a9bddc8.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2"></td><td colspan="4">AA component</td><td colspan="4">Liquid crystal component</td></tr><tr><td>Compound</td><td>X<sub>M</sub></td><td>A<sub>0</sub>/nm<sup>2</sup></td><td>A<sub>C</sub>/nm<sup>2</sup></td><td>π<sub>C</sub>/mN·m<sup>−1</sup></td><td>C<sub>S</sub>′/m·N<sup>−1</sup></td><td>A<sub>0</sub>/nm<sup>2</sup></td><td>A<sub>C</sub>/nm<sup>2</sup></td><td>π<sub>C</sub>/mN·m<sup>−1</sup></td><td>C<sub>S</sub>′/m·N<sup>−1</sup></td></tr><tr><td rowspan="6">N52/AA</td><td>0.1</td><td>0.20</td><td>0.16</td><td>26.0</td><td>9.6</td><td>0.24</td><td>0.22</td><td>7.5</td><td>10.0</td></tr><tr><td>0.2</td><td>0.17</td><td>0.14</td><td>26.1</td><td>9.9</td><td>0.25</td><td>0.23</td><td>7.7</td><td>10.3</td></tr><tr><td>0.3</td><td>0.15</td><td>0.12</td><td>26.5</td><td>9.4</td><td>0.26</td><td>0.24</td><td>7.7</td><td>10.6</td></tr><tr><td>0.4</td><td>0.13</td><td>0.11</td><td>25.6</td><td>9.1</td><td>0.27</td><td>0.25</td><td>7.6</td><td>10.6</td></tr><tr><td>0.5</td><td>0.11</td><td>0.09</td><td>25.7</td><td>10.8</td><td>0.29</td><td>0.26</td><td>7.4</td><td>12.9</td></tr><tr><td>0.6</td><td>0.09</td><td>0.07</td><td>25.4</td><td>11.3</td><td>0.29</td><td>0.26</td><td>7.6</td><td>12.5</td></tr><tr><td rowspan="6">N53/AA</td><td>0.1</td><td>0.21</td><td>0.17</td><td>26.2</td><td>8.4</td><td>0.25</td><td>0.23</td><td>2.7</td><td>20.8</td></tr><tr><td>0.2</td><td>0.18</td><td>0.15</td><td>25.5</td><td>8.3</td><td>0.26</td><td>0.24</td><td>2.6</td><td>20.9</td></tr><tr><td>0.3</td><td>0.15</td><td>0.13</td><td>25.9</td><td>8.4</td><td>0.25</td><td>0.24</td><td>2.6</td><td>19.8</td></tr><tr><td>0.4</td><td>0.12</td><td>0.10</td><td>26.0</td><td>8.8</td><td>0.27</td><td>0.26</td><td>3.7</td><td>13.4</td></tr><tr><td>0.5</td><td>0.10</td><td>0.08</td><td>26.6</td><td>9.0</td><td>0.28</td><td>0.26</td><td>3.6</td><td>14.2</td></tr><tr><td>0.6</td><td>0.09</td><td>0.07</td><td>25.9</td><td>9.0</td><td>0.28</td><td>0.26</td><td>3.3</td><td>16.2</td></tr><tr><td rowspan="6">N54/AA</td><td>0.1</td><td>0.21</td><td>0.17</td><td>26.8</td><td>8.2</td><td>0.25</td><td>0.24</td><td>2.7</td><td>12.7</td></tr><tr><td>0.2</td><td>0.18</td><td>0.15</td><td>26.8</td><td>8.2</td><td>0.25</td><td>0.25</td><td>2.7</td><td>10.5</td></tr><tr><td>0.3</td><td>0.16</td><td>0.13</td><td>26.8</td><td>8.2</td><td>0.29</td><td>0.25</td><td>2.7</td><td>24.6</td></tr><tr><td>0.4</td><td>0.15</td><td>0.11</td><td>26.4</td><td>10.4</td><td>0.26</td><td>0.26</td><td>2.6</td><td>24.2</td></tr><tr><td>0.5</td><td>0.13</td><td>0.10</td><td>26.4</td><td>10.7</td><td>0.31</td><td>0.28</td><td>2.6</td><td>25.7</td></tr><tr><td>0.6</td><td>0.11</td><td>0.08</td><td>26.5</td><td>11.1</td><td>0.32</td><td>0.29</td><td>2.5</td><td>27.0</td></tr></table> |
5969e715b2f8ef90f0e8df6079dbb270794e68fb03688ca30ab563a648f4250d.png | simple | <table><tr><td></td><td>CKD Patients(<i>N</i> = 201)</td><td>Non-CKD(<i>N</i> = 201)</td><td><i>P</i>-value</td></tr><tr><td>Age, years</td><td>55.9 ± 9.9</td><td>52.5 ± 10.0</td><td>< 0.001</td></tr><tr><td>Male, %</td><td>55.2</td><td>45.3</td><td>0.06</td></tr><tr><td>African-American, %</td><td>60.7</td><td>51.2</td><td>0.06</td></tr><tr><td>Current cigarette smoking, %</td><td>53.7</td><td>48.8</td><td>0.32</td></tr><tr><td>Alcohol consumption, %</td><td>27.9</td><td>59.2</td><td>< 0.001</td></tr><tr><td>Physical activity ≥twice/week, %</td><td>53.0</td><td>72.9</td><td>< 0.001</td></tr><tr><td>High school education, %</td><td>58.5</td><td>81.6</td><td>< 0.001</td></tr><tr><td>History of CVD, %</td><td>43.7</td><td>7.0</td><td>< 0.001</td></tr><tr><td>History of hypertension, %</td><td>88.1</td><td>23.9</td><td>< 0.001</td></tr><tr><td>History of diabetes, %</td><td>49.3</td><td>5.5</td><td>< 0.001</td></tr><tr><td>History of hypercholesterolemia, %</td><td>65.7</td><td>30.9</td><td>< 0.001</td></tr><tr><td>Use of antihypertensive agents, %</td><td>79.6</td><td>15.4</td><td>< 0.001</td></tr><tr><td>Use of hypoglycemic agents, %</td><td>34.3</td><td>3.0</td><td>< 0.001</td></tr><tr><td>Use of lipid lowering agents, %</td><td>21.9</td><td>8.9</td><td>< 0.001</td></tr><tr><td>Use of aspirin, %</td><td>34.8</td><td>8.5</td><td>< 0.001</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>32.2 ± 7.8</td><td>28.9 ± 6.4</td><td>< 0.001</td></tr><tr><td>Systolic BP, mm Hg</td><td>132.2 ± 21.0</td><td>122.0 ± 14.7</td><td>< 0.001</td></tr><tr><td>Diastolic BP, mm Hg</td><td>77.2 ± 13.5</td><td>77.6 ± 9.4</td><td>0.77</td></tr><tr><td>LDL-cholesterol, mg/dL</td><td>101.8 ± 47.3</td><td>118.2 ± 30.2</td><td>< 0.001</td></tr><tr><td>HDL-cholesterol, mg/dL</td><td>50.3 ± 15.6</td><td>57.7 ± 18.0</td><td>< 0.001</td></tr><tr><td>Fasting plasma glucose, mg/dL</td><td>119.9 ± 46.8</td><td>103.4 ± 35.4</td><td>< 0.001</td></tr><tr><td>C-reactive protein mg/L</td><td>5.3 ± 11.7</td><td>4.1 ± 8.4</td><td>0.26</td></tr><tr><td>eGFR, mL/min/1.73 m<sup>2</sup></td><td>43.3 ± 19.3</td><td>96.7 ± 16.8</td><td>< 0.001</td></tr><tr><td>Urinary albumin, mg/24 h</td><td>74.5 (12.3, 417.4)</td><td>5.9 (4.1, 11.4)</td><td>< 0.001</td></tr></table> |
8f288a4dd63e310d3d55d4d4ce7e14729e7ad3749f240c5b4878034f864cfb48.png | simple | <table><tr><td>Percentage of practice that reflects use of guidelines by referrers</td><td>Number of responses</td><td>Percentage of respondents</td></tr><tr><td><20%</td><td>2</td><td>4%</td></tr><tr><td>20–39%</td><td>5</td><td>7%</td></tr><tr><td>40–59%</td><td>10</td><td>4%</td></tr><tr><td>60–79%</td><td>12</td><td>22%</td></tr><tr><td>80–100%</td><td>26</td><td>47%</td></tr></table> |
e3334be629e1145bdcb33aaac8dd0aa83849c4ecf964974bad083786d8efda91.png | complex | <table><tr><td>Term</td><td>Definition</td></tr><tr><td>Energy</td><td>A property of the matter expressed in calories; 1 Calorie (kcal) is the energy needed to increase the temperature of 1 kg of water by 1 °C.</td></tr><tr><td>Energy expenditure (EE)</td><td>Sum of internal heat produced (endogenous energy production) and external work. The internal heat produced is mainly a sum of basal metabolic rate (BMR) and of the thermic effect of food. It is measured by indirect calorimetry. Importantly, equations used to estimate EE cannot be considered as actual EE.</td></tr><tr><td>Energy requirement</td><td>Energy from essential nutrients necessary to maintain energy homeostasis. In health, its magnitude depends mainly on age, gender, and physical activity level; in illness, many other factors influence it.</td></tr><tr><td>Endogenous energy production</td><td>Energy that is produced from internal resources (glucose, proteins, and lipids) that are degraded to produce adenosine triphosphate (ATP). The endogenous glucose production (glycogenolysis and gluconeogenesis) is the first to be activated during fasting to provide it to glucose-dependent organs. In acute illness, endogenous glucose production is increased, but the magnitude and duration of this activation is variable.</td></tr><tr><td>Extrinsic energy provision</td><td>Includes nutrition and energy-containing medications or fluids administered to patients for non-nutritional purposes.</td></tr><tr><td>Energy target</td><td>Target for extrinsic energy provision, prescribed by physicians and expressed in kcal/day. Often the target is set to match actual energy expenditure (full target).</td></tr><tr><td>Fasting</td><td>Complete interruption of feeding: different patterns are possible, such as intermittent fasting, which is now considered a promising weight-loss strategy [4].</td></tr><tr><td>Full feeding</td><td>Delivery of energy to completely cover equation-estimated target or measured EE: as equations are inexact, only the latter enables a real appreciation of the level of delivery in relation to actual EE.</td></tr><tr><td>Nutrient restriction</td><td>Reduction of a particular or total nutrient intake without causing malnutrition or biological changes known to shorten animal life span [5]. The reduction can be relative to the subject’s previous intake before intentionally restricting calories, or relative to an average person of similar body type.</td></tr><tr><td>Hypocaloric feeding</td><td>Feeding below target, or feeding to a target that is deliberately below estimated target or measured EE. Term used to describe feeds with an energy density of ≤1 kcal/mL.</td></tr><tr><td>Overfeeding</td><td>Feeding quantities of energy that exceed 110% of measured EE.</td></tr><tr><td colspan="2">Timing of feeding interventions</td></tr><tr><td>- Early</td><td>48 h after intensive care (ICU) admission</td></tr><tr><td>- Intermediate</td><td>Days 3 to 7 after ICU admission</td></tr><tr><td>- Late</td><td>Beyond the first week in the ICU</td></tr></table> |
af6af78ab22f5475ab4edfc657e856813edb1faa12bdce8cae48c6ff110617d1.png | complex | <table><tr><td>Vitamin B12 Intake</td><td colspan="2">Model 1 (Unadjusted)</td><td colspan="2">Model 2 (Adjusted)</td></tr><tr><td>Total (μg/day)</td><td><148 pmol/L (<i>n</i> = 125)</td><td><i>p</i></td><td><148 pmol/L (<i>n</i> = 125)</td><td><i>p</i></td></tr><tr><td><1.87</td><td>1.00 (ref.)</td><td>-</td><td>1.00 (ref.)</td><td>-</td></tr><tr><td>1.87–2.88</td><td>0.70 (0.42, 1.18)</td><td>0.180</td><td>0.57 (0.32, 1.01)</td><td>0.056</td></tr><tr><td>2.88–4.40</td><td>0.60 (0.35, 1.02)</td><td>0.057</td><td>0.50 (0.28, 0.92)</td><td>0.026</td></tr><tr><td>>4.40</td><td>0.53 (0.31, 0.92)</td><td>0.024</td><td>0.40 (0.21, 0.76)</td><td>0.005</td></tr><tr><td>Meat and Meat products (μg/day)</td><td><148 pmol/L (<i>n</i> = 118)</td><td><i>p</i></td><td><148 pmol/L (<i>n</i> = 118)</td><td><i>p</i></td></tr><tr><td><0.35</td><td>1.00 (ref.)</td><td>-</td><td>1.00 (ref.)</td><td>-</td></tr><tr><td>0.35–1.03</td><td>0.72 (0.42, 1.24)</td><td>0.236</td><td>0.69 (0.38, 1.25)</td><td>0.220</td></tr><tr><td>1.03–2.10</td><td>0.84 (0.50, 1.44)</td><td>0.533</td><td>0.78 (0.43, 1.42)</td><td>0.422</td></tr><tr><td>>2.10</td><td>0.55 (0.31, 0.98)</td><td>0.043</td><td>0.41 (0.20, 0.81)</td><td>0.010</td></tr><tr><td>Fish and Fish products (μg/day)</td><td><148 pmol/L (<i>n</i> = 43)</td><td><i>p</i></td><td><148 pmol/L (<i>n</i> = 43)</td><td><i>p</i></td></tr><tr><td><0.46</td><td>1.00 (ref.)</td><td>-</td><td>1.00 (ref.)</td><td>-</td></tr><tr><td>0.46–1.06</td><td>0.61 (0.23, 1.65)</td><td>0.331</td><td>0.66 (0.23, 1.91)</td><td>0.444</td></tr><tr><td>1.06–2.45</td><td>0.86 (0.34, 2.15)</td><td>0.743</td><td>0.66 (0.23, 1.86)</td><td>0.427</td></tr><tr><td>>2.45</td><td>1.00 (0.41, 2.42)</td><td>0.992</td><td>0.70 (0.25, 1.97)</td><td>0.503</td></tr><tr><td>Milk and Milk products (μg/day)</td><td><148 pmol/L (<i>n</i> = 102)</td><td><i>p</i></td><td><148 pmol/L (<i>n</i> = 102)</td><td><i>p</i></td></tr><tr><td><0.27</td><td>1.00 (ref.)</td><td>-</td><td>1.00 (ref.)</td><td>-</td></tr><tr><td>0.27–0.53</td><td>0.84 (0.47, 1.52)</td><td>0.562</td><td>0.88 (0.46, 1.71)</td><td>0.711</td></tr><tr><td>0.53–0.88</td><td>1.12 (0.64, 1.96)</td><td>0.698</td><td>1.28 (0.70, 2.37)</td><td>0.425</td></tr><tr><td>>0.88</td><td>0.58 (0.31, 1.08)</td><td>0.086</td><td>0.49 (0.24, 1.01)</td><td>0.054</td></tr></table> |
7c2359b885af4b4ec0b67253f4bc4bcd24dec3301ed1c54854830f0f3bacc36a.png | simple | <table><tr><td>Treatment provider</td><td>No of consenting patients</td><td>Complications following tooth extractions</td><td>Complications following other treatment</td></tr><tr><td>Dental Hospital</td><td>3</td><td>0</td><td>0</td></tr><tr><td>Foundation Trust</td><td>9</td><td>1</td><td>1</td></tr><tr><td>District General</td><td>69</td><td>2</td><td>1</td></tr><tr><td>Primary Care Oral Surgery</td><td>97</td><td>4</td><td>0</td></tr></table> |
f5fda0be3789c34169793cfae3a1395f4094e52b4c94cf94b49beef7be88a369.png | complex | <table><tr><td rowspan="2" colspan="2"> </td><td colspan="5">Diabetes model</td></tr><tr><td colspan="5">(High-fat feeding with low dose STZ)</td></tr><tr><td> </td><td>Control</td><td>0 mg/kg</td><td>15 mg/kg</td><td>20 mg/kg</td><td>25 mg/kg</td><td>30 mg/kg</td></tr><tr><td>Glucose (mmol/l)</td><td>12.7 ± 0.3</td><td>14.6 ± 1.8</td><td>14.7 ± 0.6</td><td>17.2 ± 1.2 *</td><td>16.9 ± 1.5 *</td><td>25.1 ± 1.1 *†</td></tr><tr><td>Insulin (ug/l)</td><td>3.03 ± 0.51</td><td>2.68 ± 0.57</td><td>2.00 ± 0.31</td><td>1.59 ± 0.36</td><td>1.93 ± 0.26</td><td>1.04 ± 0.22 *</td></tr><tr><td>NEFA (mmol/l)</td><td>0.28 ± 0.06</td><td>0.29 ± 0.05</td><td>0.29 ± 0.02</td><td>0.29 ± 0.01</td><td>0.14 ± 0.04</td><td>0.59 ± 0.07 *#</td></tr><tr><td>Triglycerides (mmol/l)</td><td>1.79 ± 0.20</td><td>1.13 ± 0.22</td><td>0.87 ± 0.06</td><td>1.41 ± 0.15</td><td>1.79 ± 0.35</td><td>7.25 ± 1.33 *†</td></tr><tr><td>β-OHB (mmol/l)</td><td>0.26 ± 0.04</td><td>0.33 ± 0.04</td><td>0.45 ± 0.07</td><td>0.77 ± 0.06</td><td>0.98 ± 0.21</td><td>5.39 ± 0.59 *†</td></tr><tr><td>Cholesterol (mmol/l)</td><td>2.46 ± 0.13</td><td>2.07 ± 0.21</td><td>1.68 ± 0.15</td><td>2.11 ± 0.27</td><td>3.87 ± 0.58 *$</td><td>3.02 ± 0.44 €</td></tr></table> |
399641955646694ea9047023a5bc8585a78be185fc8cc23d6437ebef00255ffc.png | complex | <table><tr><td rowspan="2">Recognition of</td><td colspan="3">Responses</td><td rowspan="2">Total number of participants that responded</td></tr><tr><td>Yes, <i>n</i> (%)</td><td>No, <i>n</i> (%)</td><td>Don't know, <i>n</i> (%)</td></tr><tr><td colspan="5">1. Cervical cancer risk factors</td></tr><tr><td>Early onset of sexual activity</td><td>320 (78.2)</td><td>71 (17.4)</td><td>18 (4.4)</td><td>409</td></tr><tr><td>Infection with a sexually transmitted germ/virus (HPV)</td><td>342 (82.0)</td><td>51 (12.2)</td><td>24 (5.8)</td><td>417</td></tr><tr><td>Multiple male sexual partners</td><td>378 (88.3)</td><td>45 (10.5)</td><td>5 (1.2)</td><td>428</td></tr><tr><td>Smoking cigarettes/tobacco</td><td>203 (48.6)</td><td>182 (43.5)</td><td>33 (7.9)</td><td>418</td></tr><tr><td>Grand multiparity</td><td>195 (48.6)</td><td>181 (45.2)</td><td>25 (6.2)</td><td>401</td></tr><tr><td colspan="5">2. Cervical cancer symptoms</td></tr><tr><td>Intermenstrual vaginal bleeding</td><td>344 (84.5)</td><td>48 (11.8)</td><td>15 (3.7)</td><td>407</td></tr><tr><td>Post‐menopausal vaginal bleeding</td><td>354 (84.1)</td><td>48 (11.4)</td><td>19 (4.5)</td><td>421</td></tr><tr><td>Post‐coital vaginal bleeding</td><td>324 (76.1)</td><td>76 (17.8)</td><td>26 (6.1)</td><td>426</td></tr><tr><td>Excessive vaginal discharge, often with offensive smell</td><td>347 (83.0)</td><td>53 (12.7)</td><td>18 (4.3)</td><td>418</td></tr><tr><td>Lower abdominal pain</td><td>368 (87.6)</td><td>45 (10.7)</td><td>7 (1.7)</td><td>420</td></tr><tr><td>Pain in the genital during sexual intercourse (dyspareunia)</td><td>300 (71.1)</td><td>95 (22.5)</td><td>27 (6.6)</td><td>422</td></tr></table> |
0492946120b720d72f5c02c58b4d801c25903ae8923a3bba96b64d2f6dfc1643.png | complex | <table><tr><td>Sample</td><td colspan="2">Plaque samples</td><td colspan="2">Saliva samples</td></tr><tr><td></td><td>Day 1</td><td>Day 22</td><td>Day 1</td><td>Day 22</td></tr><tr><td>Dexolac 2</td><td>45,167 ± 8,156</td><td>66,500 ± 7,914</td><td>21,167 ± 4,019</td><td>31,667 ± 3,601</td></tr><tr><td>Lactodex 2</td><td>50,727 ± 9,931</td><td>65,273 ± 5,605</td><td>23,909 ± 4,549</td><td>31,000 ± 2,793</td></tr><tr><td>Lactogen 3</td><td>48,615 ± 6,449</td><td>69,231 ± 6,906</td><td>23,154 ± 3,105</td><td>33,154 ± 3,716</td></tr></table> |
23a23555de99931da56bffc5cf4b836bf4be61f63464ecf69d8340ce640f777f.png | simple | <table><tr><td>Variants</td><td>Clinical significance</td><td>Number of samples</td></tr><tr><td>BRCA1 c.5266dupC</td><td>Pathogenic</td><td>2</td></tr><tr><td>BRAC1 c.5095C>T</td><td>Pathogenic</td><td>1</td></tr><tr><td>BRCA1 c.3916_3917del</td><td>Pathogenic</td><td>1</td></tr><tr><td>BRCA2 c.6988A>G</td><td>VUS</td><td>1</td></tr><tr><td>BRCA2 c.8482A>G</td><td>VUS</td><td>1</td></tr><tr><td>BRCA2 c.8518A>G</td><td>VUS</td><td>1</td></tr></table> |
a4c01a32819522abc80742fbc3d8966a67d7c52e93678c30c8dfeae0229fece0.png | complex | <table><tr><td rowspan="3">Antibacterial Result</td><td colspan="2">Gram-negative</td><td colspan="2">Gram-positive</td></tr><tr><td><i>E. coli</i>ATCC 25922</td><td><i>P. aeruginosa</i>ATCC 27853</td><td><i>S. aureus</i>ATCC 25923</td><td><i>B. subtilis</i>ATCC 6633</td></tr><tr><td>MIC (μg/mL)</td><td>64</td><td>500</td><td>32</td><td>16</td></tr></table> |
a53024c051b01ad96f55241f931636259df8ca0b4500761f8eb51ae7bd0e7f24.png | simple | <table><tr><td>Heating current of the emitter I (mA)</td><td>0.8</td><td>0.9</td><td>1.0</td><td>1.1</td></tr><tr><td>Steady temperature T (K)</td><td>316.3087</td><td>323.0872</td><td>330.387</td><td>339.1644</td></tr><tr><td>G<sub>con</sub> (W·K<sup>−1</sup>)</td><td>1.34 × 10<sup>−6</sup></td><td>1.33 × 10<sup>−6</sup></td><td>1.32 × 10<sup>−6</sup></td><td>1.31 × 10<sup>−6</sup></td></tr><tr><td>G<sub>fr</sub> (W·K<sup>−1</sup>)</td><td>1.49 × 10<sup>−8</sup></td><td>1.59 × 10<sup>−8</sup></td><td>1.70 × 10<sup>−8</sup></td><td>1.84 × 10<sup>−8</sup></td></tr></table> |
0f224a6ad3a655ef19bea4bde68a19bedfc357e12d12dddf59508fb2ce3bed00.png | simple | <table><tr><td>Items of the scale</td><td>Domains</td></tr><tr><td>1. I feel guilty because I have HIV.</td><td>Internalized stigma</td></tr><tr><td>2. People’s attitudes about HIV make me feel worse about myself.</td><td>Internalized stigma</td></tr><tr><td>3. People with HIV lose their jobs when their employers learn.</td><td>Perceived stigma</td></tr><tr><td>4. I feel I am not as good a person as others because I have HIV.</td><td>Internalized stigma</td></tr><tr><td>5. People with HIV are treated like outcasts.</td><td>Perceived stigma</td></tr><tr><td>6. Most people think that a person who has HIV is dirty.</td><td>Perceived stigma</td></tr><tr><td>7. It is easier to avoid new friendships than worry about telling someone that I have HIV.</td><td>Internalized stigma</td></tr><tr><td>8. Having HIV makes me feel unclean.</td><td>Internalized stigma</td></tr><tr><td>9. Since learning I have HIV, I feel set apart and isolated from the rest of the world.</td><td>Internalized stigma</td></tr><tr><td>10. Most people think that a person with HIV is disgusting.</td><td>Perceived stigma</td></tr><tr><td>11. Having HIV makes me feel that I am a bad person.</td><td>Internalized stigma</td></tr><tr><td>12. Most people with HIV are rejected when others find out.</td><td>Perceived stigma</td></tr><tr><td>13. Most people are uncomfortable around someone with HIV.</td><td>Perceived stigma</td></tr><tr><td>14. Having HIV in my body is disgusting to me.</td><td>Internalized stigma</td></tr></table> |
54069fb6b161e8eeae56e6e41c7f8a3bc98a8b17bc695d75909e82f47d5d205b.png | simple | <table><tr><td>Name</td><td>Sequence 53</td></tr><tr><td>rmhS100 — F</td><td>ATgTCTTCCATCAgTATTCAggg</td></tr><tr><td>rmhS100 — R</td><td>TCTCCATCACTTTgTCCACC</td></tr><tr><td>rmhS100 — pr</td><td>[FAM] TCTTCAgCTTgTgCTTgTCACCCT [BH1]</td></tr><tr><td>Pmp22 — TM — S</td><td>gTgCTAgTgTTgCTCTTC</td></tr><tr><td>Pmp22 — TM — A</td><td>ggATgTggTACAgTTCTg</td></tr><tr><td>Pmp22 — TMpr</td><td>[FAM] CTCCACCATCgTCAgCCAAT [BH1]</td></tr><tr><td>rPmp2 — TM — S</td><td>ggAgACTATATCACCATTAgA</td></tr><tr><td>rPmp2 — TM — A</td><td>TCCAgCAACTTTCTCTTTA</td></tr><tr><td>Pmp2 — TMpr</td><td>[FAM] CCACTTCTgCACTTgCTTCA [BH1]</td></tr><tr><td>rmh18S — TMF</td><td>gCCgCTAgAggTgAAATTCTTg</td></tr><tr><td>rmh18S — TMR</td><td>CATTCTTggCAAATgCTTTCg</td></tr><tr><td>rmh18S TMpr</td><td>[HEX] ACCggCgCAAgACggACCAg [BH2]</td></tr></table> |
08847966fd5d950bc11e6c5ac51df23053b6228f25343a6e161d2d9f8d3958ea.png | complex | <table><tr><td> </td><td colspan="4">Follow up</td></tr><tr><td>Type of intervention</td><td>3 months</td><td>6 months</td><td>1 year</td><td>5 years</td></tr><tr><td>2</td><td>6 [−9.8; 21.8]</td><td>6.2 [−9.1; 21.4]</td><td>6.6 [−7.7; 20.8]</td><td>9.7 [−2.1; 21.5]</td></tr><tr><td>3</td><td>−11.8 [−19.6; −3.9]</td><td>−11.3 [−19; −3.6]</td><td>−10.4 [−17.7; −3.1]</td><td>−3.4 [−9.6; 2.9]</td></tr><tr><td>4</td><td>−11.9 [−23.5; −0.2]</td><td>−11.1 [−22.3; 0.2]</td><td>−9.5 [−20; 1]</td><td>3.3 [−5.2; 11.8]</td></tr><tr><td>6</td><td>1.2 [−6.1; 8.4]</td><td>1.5 [−5.7; 8.6]</td><td>2.1 [−4.8; 9]</td><td>7 [0.6; 13.4]</td></tr><tr><td>7</td><td>0.6 [−5.2; 6.5]</td><td>0.6 [−5.2; 6.4]</td><td>0.4 [−5.3; 6.2]</td><td>−0.5 [−6.1; 5.2]</td></tr></table> |
5bab5b15458afb303913d4fbc30298251601900471fae81837ea78ac10a41ee0.png | simple | <table><tr><td>GroupsParameters</td><td>Vitamin D ≤ 12.5 (nmol/l)</td><td>12.5<vitamin D ≤ 25</td><td>25<vitamin D ≤ 35</td><td>35.1<vitamin D ≤ 150</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>27.32 ± 5.02</td><td>26.44 ± 4.52</td><td>27.66 ± 5.16</td><td>26.99 ± 4.93</td></tr><tr><td>Calcium intake (mg/day)</td><td>503.39 ± 303.1*</td><td>577.93 ± 304.9*</td><td>595.84 ± 313.6*</td><td>714.67 ± 330.8</td></tr></table> |
bde67b9996c977b364a70349f2c50cdfcb2c957cbcf81176f44a7fe0ce888bd5.png | simple | <table><tr><td>Characteristic</td><td>Cases (<i>n</i> = 300)</td><td>Controls (<i>n</i> = 299)</td><td><i>P</i></td></tr><tr><td>Age (years)</td><td>57.9 (5.2)</td><td>57.8 (5.2)</td><td>0.82</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>26.0 (3.3)</td><td>26.5 (3.6)</td><td>0.10</td></tr><tr><td>Cigarettes per day</td><td>19.2 (8.9)</td><td>19.5 (7.9)</td><td>0.63</td></tr><tr><td>Years of smoking</td><td>35.3 (8.9)</td><td>36.7 (8.0)</td><td>0.04</td></tr><tr><td>History of BPH (% yes)</td><td>4.7</td><td>3.0</td><td>0.29</td></tr><tr><td>History of diabetes (% yes)</td><td>4.0</td><td>3.0</td><td>0.51</td></tr><tr><td>Family history of prostate cancer (% yes)</td><td>7.6</td><td>4.9</td><td>0.21</td></tr><tr><td>Physical activity (% active)1</td><td>62.0</td><td>57.2</td><td>0.23</td></tr><tr><td>Education > primary school (% yes)</td><td>41.0</td><td>30.4</td><td>0.007</td></tr><tr><td>Serum cholesterol (mmol/L)</td><td>6.27 (1.09)</td><td>6.24 (1.30)</td><td>0.74</td></tr><tr><td>Serum <i>β</i>-carotene (<i>μ</i>g/L)</td><td>242 (197)</td><td>214 (130)</td><td>0.04</td></tr><tr><td>Serum <i>α</i>-tocopherol (mg/L)</td><td>11.8 (2.4)</td><td>11.9 (2.4)</td><td>0.87</td></tr><tr><td>Alcohol consumption (g/d)</td><td>16.3 (20.4)</td><td>16.7 (19.2)</td><td>0.80</td></tr><tr><td>Energy intake (kcal/d)</td><td>2675 (757)</td><td>2696 (819)</td><td>0.74</td></tr><tr><td>Fat intake (g/d)2</td><td>117 (15)</td><td>117 (15)</td><td>0.64</td></tr><tr><td>Saturated fat intake (g/d)2</td><td>49.7 (12.1)</td><td>50.4 (12.3)</td><td>0.50</td></tr><tr><td>Fruit and vegetable intake (g/d)2</td><td>242 (132)</td><td>241 (128)</td><td>0.94</td></tr><tr><td><i>β</i>-Carotene intake (<i>μ</i>g/d)2</td><td>2097 (1382)</td><td>2044 (1333)</td><td>0.62</td></tr><tr><td>Total dairy product intake (g/d)2<sup>,</sup>3</td><td>780</td><td>771</td><td>0.74</td></tr><tr><td>Red meat intake (g/d)2<sup>,</sup>4</td><td>32.0</td><td>31.5</td><td>0.79</td></tr><tr><td>Estimated phytanic acid intake (mg/d)2<sup>,</sup>5</td><td>129 (54)</td><td>133 (56)</td><td>0.45</td></tr><tr><td>Serum phytanic acid (% total fatty acids)6</td><td>0.08 (0.04)</td><td>0.08 (0.04)</td><td>0.83</td></tr><tr><td>Serum phytanic acid (<i>μ</i>g/mL)</td><td>3.02 (1.57)</td><td>3.09 (1.77)</td><td>0.97</td></tr><tr><td>Serum pristanic acid (% total fatty acids)6</td><td>0.01 (0.007)</td><td>0.01 (0.008)</td><td>0.45</td></tr><tr><td>Serum pristanic acid (<i>μ</i>g/mL)</td><td>0.50 (0.32)</td><td>0.51 (0.28)</td><td>0.59</td></tr></table> |
b84148f7a0a6b5f89f3aaeb9bc98407fb55df748e62a1513a9da4fb0af63f571.png | complex | <table><tr><td> </td><td>Identifiable (n = 296)† n (%)</td><td>Anonymous (n = 315) †† n (%)</td><td>Chi<sup>2</sup>statistic (degrees of freedom), P value</td><td>Odds ratio (95% confidence interval)</td><td>Adjusted* odds ratio (95% confidence interval)</td></tr><tr><td colspan="6">Barriers to Care</td></tr><tr><td>It is difficult to schedule an appointment</td><td>66 (23.9)</td><td>63 (22.0)</td><td>0.31 (1), P = 0.580</td><td>0.89 (0.60-1.33)</td><td>0.95 (0.64-1.41)</td></tr><tr><td>It is difficult to get time off</td><td>86 (31.1)</td><td>108 (36.9)</td><td>2.14 (1), P = 0.143</td><td>1.30 (0.92-1.84)</td><td>1.34 (0.94-1.91)</td></tr><tr><td>I don’t trust mental health professionals</td><td>36 (12.7)</td><td>42 (14.3)</td><td>0.34 (1), P = 0.560</td><td>1.15 (0.71-1.86)</td><td>1.17 (0.73-1.93)</td></tr><tr><td>My visit would not remain confidential</td><td>69 (24.7)</td><td>76 (26.0)</td><td>0.13 (1), P = 0.722</td><td>1.07 (0.73-1.56)</td><td>1.11 (0.76-1.63)</td></tr><tr><td>Leaders discourage the use of mental health services</td><td>13 (4.6)</td><td>27 (9.3)</td><td>4.76 (1), P = 0.029</td><td>2.11 (1.06-4.18)</td><td>2.23 (1.12-4.43)</td></tr><tr><td colspan="6">Perceived social stigma</td></tr><tr><td>It would be too embarrassing</td><td>93 (32.5)</td><td>122 (41.6)</td><td>5.16 (1), P = 0.023</td><td>1.48 (1.05-2.08)</td><td>1.55 (1.10-2.18)</td></tr><tr><td>It would affect my career</td><td>116 (41.1)</td><td>123 (41.8)</td><td>0.03 (1), P = 0.864</td><td>1.03 (0.74-1.43)</td><td>1.08 (0.77-1.51)</td></tr><tr><td>Others would have less confidence in me</td><td>151 (53.0)</td><td>171 (58.0)</td><td>1.46 (1), P = 0.227</td><td>1.22 (0.88-1.70)</td><td>1.29 (0.93-1.80)</td></tr><tr><td>My leaders would treat me differently</td><td>152 (53.7)</td><td>169 (57.3)</td><td>0.75 (1), P = 0.387</td><td>1.16 (0.83-1.61)</td><td>1.21 (0.87-1.69)</td></tr><tr><td>My leaders would blame me</td><td>67 (23.5)</td><td>74 (25.3)</td><td>0.26 (1), P = 0.608</td><td>1.10 (0.76-1.62)</td><td>1.18 (0.81-1.74)</td></tr><tr><td>I would be seen as weak</td><td>95 (34.2)</td><td>136 (46.6)</td><td>9.09 (1), P = 0.003</td><td>1.68 (1.20-2.35)</td><td>1.78 (1.26-2.50)</td></tr></table> |
88edc5795422cba7647ad8226617656e8ea03d4dd417e0a94618d1aff133fac3.png | simple | <table><tr><td>Biomarkera</td><td>Mean ± SD</td><td>Median (min/max)</td></tr><tr><td>IL-6 (pg/mL)</td><td>2.42 ± 1.85</td><td>1.92 (0.25/10.0)</td></tr><tr><td>TNF-α (pg/mL)b</td><td>1.92 ± 1.64</td><td>1.41 (0.5/14.3)</td></tr><tr><td>sTNF-RII (pg/mL)</td><td>3,610 ± 1,489</td><td>3,235 (657/11,584)</td></tr><tr><td>sP-selectin (ng/mL)</td><td>45.0 ± 16.6</td><td>42.5 (6.0/119.9)</td></tr><tr><td>CRP (ng/mL)c</td><td>2,434 ± 3,181</td><td>1,403 (250/26,799)</td></tr><tr><td>Cu, Zn-SOD (U/g Hb)</td><td>4,459 ± 1,688</td><td>4,288 (669/13,138)</td></tr><tr><td>GPx-1 (U/g Hb)</td><td>19.2 ± 7.6</td><td>17.8 (5.5/50.7)</td></tr></table> |
a517a208330aecf7f827422111acdd958c66df9309fc98f8cc19516cf21a26b8.png | simple | <table><tr><td>permanent transect ID</td><td>latitude of origin (° N)</td><td>longitude of origin (° W)</td><td>elevation (m)</td><td>burn severity class</td><td>burn severity score</td><td>soil pH (± s.e.)</td></tr><tr><td>101</td><td>69.995</td><td>150.283</td><td>359</td><td>severe</td><td>1.8</td><td>4.6 (0.18)</td></tr><tr><td>114</td><td>69.997</td><td>150.307</td><td>325</td><td>severe</td><td>1.5</td><td>4.5 (0.08)</td></tr><tr><td>103</td><td>68.954</td><td>150.207</td><td>403</td><td>moderate</td><td>3.1</td><td>4.7 (0.05)</td></tr><tr><td>104</td><td>68.951</td><td>150.210</td><td>412</td><td>moderate</td><td>2.5</td><td>4.9 (0.12)</td></tr><tr><td>108</td><td>68.952</td><td>150.208</td><td>414</td><td>unburned</td><td>4.8</td><td>4.4 (0.15)</td></tr><tr><td>109</td><td>68.933</td><td>150.273</td><td>435</td><td>unburned</td><td>5</td><td>4.5 (0.10)</td></tr></table> |
21635569144ca2ce646973459a6f76ee0ea6ef2405fb48a0df877d88b5715b01.png | simple | <table><tr><td>Enzyme</td><td>Recognition site</td><td>Sensitivity to methylation</td></tr><tr><td>Aci I</td><td>5'-CCGC-3'</td><td>CpG</td></tr><tr><td>Bfa I</td><td>5'-CTAG-3'</td><td>none</td></tr><tr><td>BstU I</td><td>5'-CGCG-3'</td><td>CpG</td></tr><tr><td>Cfo I</td><td>5'-GCGC-3'</td><td>CpG</td></tr><tr><td>Hae III</td><td>5'-GGCC-3'</td><td>none</td></tr><tr><td>MspI</td><td>5'-CCGG-3'</td><td>CpNpG</td></tr><tr><td>Sau3A I</td><td>5'-GATC-3'</td><td>none</td></tr></table> |
f74ca4d46057baabdb4a5d50e2aebb74c2709c2dac7db39cad1eea105947bc3f.png | simple | <table><tr><td></td><td>Number of cases</td><td>Median (IQR) ng/mL</td></tr><tr><td>sAxl</td><td>1067</td><td></td></tr><tr><td> Healthy controls</td><td>75</td><td>40.15 (35.22 - 46.85)</td></tr><tr><td> Tumors patients:</td><td>402</td><td></td></tr><tr><td> All HCC</td><td>347*</td><td>78.69 (55.09 - 101.5)</td></tr><tr><td> HCC with cirrhosis</td><td>272</td><td>83.37 (62.13 - 107.1)</td></tr><tr><td> HCC w/o cirrhosis</td><td>35</td><td>61.92 (43.13 - 81.09)</td></tr><tr><td> BCLC A</td><td>45</td><td>82.57 (52.13 - 110.2)</td></tr><tr><td> BCLC B</td><td>45</td><td>73.46 (50.59 - 87.24)</td></tr><tr><td> BCLC C</td><td>67</td><td>77.08 (55.09 - 96.33)</td></tr><tr><td> BCLC D</td><td>12</td><td>114.50 (89.69 - 134.6)</td></tr><tr><td> CCA</td><td>44</td><td>41.02 (33.89 - 48.11)</td></tr><tr><td> Adenoma</td><td>11</td><td>31.41 (25.95 - 36.57)</td></tr><tr><td> Chronic liver diseases</td><td>400</td><td></td></tr><tr><td> Fibrosis stages:</td><td></td><td></td></tr><tr><td> F0</td><td>54</td><td>40.70 (35.56 - 51.98)</td></tr><tr><td> F1</td><td>75</td><td>46.20 (38.64 - 55.07)</td></tr><tr><td> F2</td><td>80</td><td>46.76 (40.37 - 60.06)</td></tr><tr><td> F3</td><td>36</td><td>54.67 (43.45 - 74.92)</td></tr><tr><td> F4 (cirrhosis w/o HCC)</td><td>155</td><td>94.74 (66.38 - 132.5)</td></tr><tr><td> Liver disease etiology:</td><td>190</td><td></td></tr><tr><td> Viral hepatitis</td><td>26</td><td>47.87 (42.30 - 61.75)</td></tr><tr><td> AIH</td><td>18</td><td>48.40 (36.16 - 84.20)</td></tr><tr><td> Cholestatic liver disease</td><td>30</td><td>40.97 (36.01 - 51.06)</td></tr><tr><td> NAFLD</td><td>116</td><td>43.15 (37.72 - 53.85)</td></tr><tr><td>AFP</td><td>326</td><td></td></tr><tr><td> Healthy controls</td><td>28</td><td>2.60 (1.500 - 3.475)</td></tr><tr><td> All HCC</td><td>274</td><td>12.90 (5.275 - 173.3)</td></tr><tr><td> HCC with cirrhosis</td><td>194</td><td>11.50 (0 - 49.33)</td></tr><tr><td> HCC w/o cirrhosis</td><td>28</td><td>23.60 (3.900 - 4743)</td></tr><tr><td> F4 (cirrhosis w/o HCC)</td><td>24</td><td>4.65 (3.025 - 6.650)</td></tr></table> |
16a7d661818b7db32f9c2be04a6b38614f0c9fdf53ecf672d0a5a5e60ce59b5b.png | simple | <table><tr><td></td><td>Preoperative</td><td>6 months</td><td>12 months</td><td>18 months</td></tr><tr><td>Upper limb (<i>n</i>)</td><td>15</td><td>12</td><td>7</td><td>1</td></tr><tr><td> L-Dex [mean (range)]</td><td>41.2 (18–75)</td><td>35.3 (14–49)</td><td>25.1 (13–45)</td><td>27</td></tr><tr><td> Significance</td><td>–</td><td><i>p</i> = 0.068</td><td><i>p</i> = 0.018</td><td>–</td></tr><tr><td> Mean excess volume [ml (range)]</td><td>1139.5 (645–1755)</td><td>67.9 (−697 to 422)</td><td>18.7 (−244 to 218)</td><td>−339<sup>a</sup></td></tr><tr><td> Mean excess volume [% (range)]</td><td>44.2 (27–67)</td><td>3.6 (−21 to 21)</td><td>1.3 (−5 to 8)</td><td>−11<sup>a</sup></td></tr><tr><td> Significance</td><td>–</td><td><i>p</i> <i><</i> 0.001</td><td><i>p</i> = 0.001</td><td>–</td></tr><tr><td>Lower limb (<i>n</i>)</td><td>6</td><td>5</td><td>1</td><td>0</td></tr><tr><td> L-Dex [mean (range)]</td><td>46.9 (12–97)</td><td>49.3 (33–71)</td><td>39.0</td><td>–</td></tr><tr><td> Significance</td><td>–</td><td><i>p</i> = 0.746</td><td>–</td><td>–</td></tr><tr><td> Mean excess volume [ml (range)]</td><td>4058 (2068–8294)</td><td>400 (−112 to 867)</td><td>−103</td><td>–</td></tr><tr><td> Mean excess volume [% (range)]</td><td>47.3 (23–83)</td><td>4.3 (−1 to 11)</td><td>−1.0</td><td>–</td></tr><tr><td> Significance</td><td>–</td><td><i>p</i> = 0.018</td><td>–</td><td>–</td></tr></table> |
5ab0ab02c0603ec6c52f8847b70d24798d0b222a583d00b5039307143820d465.png | simple | <table><tr><td>Samples</td><td>Vitamin A</td><td>Vitamin B<sub>2</sub></td><td>Vitamin B<sub>3</sub></td><td>Vitamin C</td></tr><tr><td>Control</td><td>0.01</td><td>0.01</td><td>0.05</td><td>62.54</td></tr><tr><td>A</td><td>1.98</td><td>30.25</td><td>0.18</td><td>40.72</td></tr><tr><td>B</td><td>2.00</td><td>25.42</td><td>0.15</td><td>34.12</td></tr><tr><td>C</td><td>2.20</td><td>22.12</td><td>0.15</td><td>30.56</td></tr><tr><td>D</td><td>3.15</td><td>12.25</td><td>0.20</td><td>22.14</td></tr></table> |
5acc5abe3ebb741c1a2fd6fe8853b675cec299b7d1ab04ebeddef48fed0a3852.png | complex | <table><tr><td>Sex</td><td>Woman</td></tr><tr><td>Age</td><td>33 years</td></tr><tr><td colspan="2">EPILEPSY</td></tr><tr><td>Brain insult</td><td>TBI when she was 1 year old</td></tr><tr><td>Febrile seizure</td><td>No</td></tr><tr><td>First epileptic seizure</td><td>9 years old</td></tr><tr><td>Age of onset Auras</td><td>6 years old</td></tr><tr><td>Duration of seizures</td><td>24 years</td></tr><tr><td>Frecuency</td><td>On <i>cluster/4–5</i> month</td></tr><tr><td>Complex partial seizures</td><td>Yes</td></tr><tr><td>Antiepileptic treatment</td><td>Trileptal, Keppra, Noiafren and Stilnox</td></tr><tr><td>Neurological examination</td><td>Normal</td></tr><tr><td>Ictal EEG</td><td>Video EEG predominance interictal activity in left temporal lobe</td></tr><tr><td>Interictal EEG</td><td>Video EEG ictal activity in left temporal lobe</td></tr><tr><td>MRI</td><td>Reduction of left hippocampal size, with hypointensity and loss of internal differentiation</td></tr><tr><td>Interictal SPECT HMpao</td><td>Left anterior temporal lobe hypoperfusion</td></tr><tr><td colspan="2">SURGERY</td></tr><tr><td>Surgery procedure</td><td>Selective amigdalohippocampectomy transilvian (Yasargil technique)</td></tr><tr><td>Size of resection</td><td>Resection of the hippocampal gyrus, the subiculum and the parahippocampal gyrus. Resection of the anterior portion of the left hippocampus with preservation of the dorsal portion and tail</td></tr><tr><td>Histology</td><td>Hippocampal sclerosis. Massive pyramidal cells loss in Ammon's sectors (CA1 to CA4), astrocytosis and neuronal dispersion of dentate gyrus</td></tr></table> |
3bf776b13e660a500fa695cebd45256e528fe83aeeeacdc9c40389c34a4569b1.png | complex | <table><tr><td>Variables</td><td colspan="2">Screening phase (<i>n</i> = 30)</td><td colspan="2">Training cohort (<i>n</i> = 84)</td><td colspan="2">Testing cohort (<i>n</i> = 214)</td><td colspan="2">Additional validation cohort (<i>n</i> = 99)</td></tr><tr><td></td><td>Cases (%)</td><td>Controls (%)</td><td>Cases (%)</td><td>Controls (%)</td><td>Cases (%)</td><td>Controls (%)</td><td>Cases (%)</td><td>Controls (%)</td></tr><tr><td>Number</td><td>20</td><td>10</td><td>36</td><td>42</td><td>101</td><td>113</td><td>41</td><td>50</td></tr><tr><td>Gender</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Male</td><td>14 (70)</td><td>6 (60)</td><td>25 (69)</td><td>27 (64.3)</td><td>77 (76.2)</td><td>75 (66.4)</td><td>24 (58.5)</td><td>26 (52)</td></tr><tr><td>Female</td><td>6 (30)</td><td>4 (40)</td><td>11 (31)</td><td>15 (35.7)</td><td>24 (23.8)</td><td>38 (33.6)</td><td>17 (41.5)</td><td>24 (48)</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>< 65</td><td>13 (65)</td><td>5 (50)</td><td>20 (55.6)</td><td>31 (73.8)</td><td>65 (64.4)</td><td>81 (71.2)</td><td>25 (61)</td><td>34 (68)</td></tr><tr><td>≥ 65</td><td>7 (35)</td><td>5 (50)</td><td>16 (44.4)</td><td>11 (26.2)</td><td>36 (35.6)</td><td>32 (28.8)</td><td>16 (39)</td><td>16 (32)</td></tr><tr><td>Smoking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Smoker</td><td>9 (45)</td><td></td><td>14 (38.9)</td><td></td><td>39 (38.6)</td><td></td><td>17 (41.5)</td><td></td></tr><tr><td>Non-smoker</td><td>8 (40)</td><td></td><td>15 (41.7)</td><td></td><td>47 (46.5)</td><td></td><td>22 (53.7)</td><td></td></tr><tr><td>NA</td><td>3 (15)</td><td></td><td>7 (19.4)</td><td></td><td>15 (14.9)</td><td></td><td>2 (4.8)</td><td></td></tr><tr><td>Drinking</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Drinker</td><td>3 (15)</td><td></td><td>7 (19.4)</td><td></td><td>23 (22.7)</td><td></td><td>7 (17.1)</td><td></td></tr><tr><td>Non-drinker</td><td>11 (55)</td><td></td><td>23 (63.9)</td><td></td><td>71 (70.3)</td><td></td><td>26 (63.4)</td><td></td></tr><tr><td>NA</td><td>6 (30)</td><td></td><td>6 (16.7)</td><td></td><td>7 (7)</td><td></td><td>8 (19.5)</td><td></td></tr><tr><td>Differential</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>well</td><td>10 (50)</td><td></td><td>19 (52.8)</td><td></td><td>48 (47.5)</td><td></td><td>19 (46.3)</td><td></td></tr><tr><td>poor</td><td>7 (35)</td><td></td><td>14 (38.9)</td><td></td><td>42 (41.6)</td><td></td><td>14 (34.2)</td><td></td></tr><tr><td>NA</td><td>3 (15)</td><td></td><td>3 (8.3)</td><td></td><td>11 (10.9)</td><td></td><td>8 (19.5)</td><td></td></tr><tr><td>Location</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Up</td><td>2 (10)</td><td></td><td>3 (8.3)</td><td></td><td>6 (5.9)</td><td></td><td>4 (9.8)</td><td></td></tr><tr><td>Middle</td><td>9 (45)</td><td></td><td>15 (41.7)</td><td></td><td>31 (30.7)</td><td></td><td>16 (39)</td><td></td></tr><tr><td>Down</td><td>7 (35)</td><td></td><td>14 (38.9)</td><td></td><td>49 (48.5)</td><td></td><td>15 (36.6)</td><td></td></tr><tr><td>NA</td><td>2 (10)</td><td></td><td>4 (11.1)</td><td></td><td>15 (14.9)</td><td></td><td>6 (14.6)</td><td></td></tr><tr><td>TNM stage</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>I</td><td>8 (40)</td><td></td><td>15 (41.7)</td><td></td><td>46 (45.5)</td><td></td><td>18 (43.9)</td><td></td></tr><tr><td>II</td><td>7 (35)</td><td></td><td>14 (38.9)</td><td></td><td>32 (31.7)</td><td></td><td>18 (43.9)</td><td></td></tr><tr><td>III</td><td>5 (25)</td><td></td><td>7 (19.4)</td><td></td><td>23 (22.8)</td><td></td><td>5 (12.2)</td><td></td></tr></table> |
a73e87a17d18e2059830090b0242d7bd63d7002ea73595c75d798cbb0b56b982.png | simple | <table><tr><td>Lane</td><td>1</td><td>2</td><td>3</td></tr><tr><td>1</td><td>1.00</td><td>0.72</td><td>0.37</td></tr><tr><td>2</td><td>0.72</td><td>1.00</td><td>0.45</td></tr><tr><td>3</td><td>0.37</td><td>0.45</td><td>1.00</td></tr></table> |
4612e4f90beb0d0ea59043ed20e9f05a566b0b7ff39872659ad3719627092802.png | simple | <table><tr><td></td><td>Arthritic patient volunteers (n = 13)</td><td>Healthy volunteers (n = 18)</td></tr><tr><td>Age (y)*</td><td>64.8 (6.4)</td><td>33.8 (7.9)</td></tr><tr><td>Body mass index*, kg/m<sup>2</sup></td><td>36.1 (5.4)</td><td>23.3 (3.0)</td></tr><tr><td>Male, n</td><td>7</td><td>6</td></tr></table> |
41cf081761f09bb5fa731e604bce5844abbf289625365a32c21ed1820b1da852.png | simple | <table><tr><td>Category</td><td><i>P</i> value</td><td>Total occurrence</td></tr><tr><td>Multicellular organismal process</td><td>7.36E−09</td><td>1048</td></tr><tr><td>Biological adhesion</td><td>7.78E−07</td><td>409</td></tr><tr><td>Cell adhesion</td><td>7.78E−07</td><td>409</td></tr><tr><td>Oxidation reduction</td><td>9.32E−06</td><td>339</td></tr><tr><td>Regulation of multicellular organismal process</td><td>2.94E−05</td><td>358</td></tr><tr><td>Developmental process</td><td>3.21E−05</td><td>1756</td></tr><tr><td>Cellular ion homeostasis</td><td>4.49E−05</td><td>117</td></tr><tr><td>Branching morphogenesis of a tube</td><td>5.10E−05</td><td>40</td></tr><tr><td>Morphogenesis of a branching structure</td><td>5.84E−05</td><td>41</td></tr><tr><td>Cellular chemical homeostasis</td><td>9.57E−05</td><td>119</td></tr></table> |
7e2ae4f3e54708b541644fb29f8fb4e1b2ea4a1f2ac75bfcfcbe596b3628d2e0.png | simple | <table><tr><td>Clinical parameters</td><td>Case(n =124 )</td></tr><tr><td>Incidence rate , per 100 person-years</td><td>5.4</td></tr><tr><td>Median (IQR), duration from starting ARV to hepatitis, years</td><td>1.3(0.5–3.5)</td></tr><tr><td>Mean ALT level at time of ALT elevation, IU/L (±SD)</td><td>73 ± 107</td></tr><tr><td>Mean AST level at time of ALT elevation, IU/L (±SD)</td><td>58 ± 49</td></tr><tr><td>Mean alkaline phosphatase level at time of ALT elevation, IU/L (±SD)</td><td>97 ± 54</td></tr><tr><td>Severity grading of chronic hepatitis **, n (%)</td><td> </td></tr><tr><td>o Mild (grade 1 or 2)</td><td>122 (98.4)</td></tr><tr><td>o Severe, at least grade 3</td><td>2 (1.6)</td></tr><tr><td>Symptoms at time of ALT elevation, n (%)</td><td> </td></tr><tr><td>o Any</td><td>64(51.6)</td></tr><tr><td>o Nausea/ vomiting</td><td>30(24.2)</td></tr><tr><td>o Fatigue</td><td>14(11.3)</td></tr><tr><td>o Anorexia</td><td>9(7.3)</td></tr><tr><td>o Flatulence</td><td>5(4.0)</td></tr><tr><td>o Weight loss</td><td>4(3.2)</td></tr><tr><td>o Jaundice</td><td>1(0.8)</td></tr><tr><td>o Liver tenderness</td><td>1(0.8)</td></tr></table> |
df7aaecac6a9589e624cd0fc7b224437e5fe9314e399bcec2978a9011a34db84.png | complex | <table><tr><td>Characteristics</td><td colspan="2">Physicians (<i>N</i> = 55)</td><td colspan="2">Nurses (<i>N</i> = 78)</td><td><i>p</i></td><td colspan="2">Total (<i>N</i> = 133)</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td></td><td>n</td><td>%</td></tr><tr><td colspan="8">Gender</td></tr><tr><td>- Male</td><td>35</td><td>63.6</td><td>2</td><td>2.6</td><td rowspan="2"><0.001</td><td>37</td><td>27.8</td></tr><tr><td>- Female</td><td>20</td><td>36.4</td><td>76</td><td>97.4</td><td>96</td><td>72.2</td></tr><tr><td>Age (mean / SD)</td><td>39.8 (10.6)</td><td>42.7 (8.6)</td><td>0.090</td><td>41.5 (9.6)</td><td></td><td></td><td></td></tr><tr><td>- 25 – 44</td><td>37</td><td>67.3</td><td>41</td><td>52.6</td><td></td><td>78</td><td>58.6</td></tr><tr><td>- 45 – 60</td><td>18</td><td>32.7</td><td>37</td><td>47.4</td><td></td><td>55</td><td>41.4</td></tr><tr><td colspan="8">Marital status</td></tr><tr><td>- Married or Cohabiting</td><td>34</td><td>61.8</td><td>54</td><td>69.2</td><td rowspan="3">0.094</td><td>88</td><td>66.2</td></tr><tr><td>- Single</td><td>21</td><td>38.2</td><td>20</td><td>25.6</td><td>41</td><td>30.8</td></tr><tr><td>- Widow/divorced/separated</td><td>0</td><td>0.0</td><td>4</td><td>5.1</td><td>4</td><td>3.0</td></tr><tr><td>Length of employment (years)</td><td colspan="2">13.9 (10.5)</td><td colspan="2">19.4 (9.4)</td><td rowspan="3">0.232</td><td colspan="2">17.1 (10.2)</td></tr><tr><td>- More than 20</td><td>18</td><td>32.7</td><td>36</td><td>46.2</td><td>54</td><td>40.6</td></tr><tr><td>- 20 or less</td><td>37</td><td>67.3</td><td>42</td><td>53.8</td><td>79</td><td>59.4</td></tr><tr><td>Ever perform or assist in MC</td><td>37</td><td>67.3</td><td>33</td><td>42.3</td><td>0.005</td><td>70</td><td>52.6</td></tr><tr><td>Ever perform or assist in NMC</td><td>8</td><td>14.5</td><td>5</td><td>6.4</td><td>0.120</td><td>13</td><td>9.8</td></tr></table> |
454f5688740a8e515c79c2d789f5d68780c01cf2e5afec7bff734a74c766d308.png | complex | <table><tr><td></td><td colspan="2">ypT0</td><td colspan="2">ypT1</td><td colspan="2">ypT2</td><td colspan="2">ypT3–4</td></tr><tr><td>Variable</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td colspan="9">Sex</td></tr><tr><td> Male</td><td>74</td><td>64.9</td><td>692</td><td>63.4</td><td>1297</td><td>65.2</td><td>5919</td><td>62.4</td></tr><tr><td> Female</td><td>40</td><td>35.1</td><td>399</td><td>36.6</td><td>692</td><td>34.8</td><td>3569</td><td>37.6</td></tr><tr><td colspan="9">Age</td></tr><tr><td> <50</td><td>20</td><td>17.5</td><td>195</td><td>17.9</td><td>377</td><td>19</td><td>1933</td><td>20.4</td></tr><tr><td> ≥50</td><td>94</td><td>82.5</td><td>896</td><td>82.1</td><td>1612</td><td>81</td><td>7555</td><td>79.6</td></tr><tr><td colspan="9">Race</td></tr><tr><td> White</td><td>99</td><td>86.8</td><td>910</td><td>83.4</td><td>1604</td><td>80.6</td><td>7764</td><td>81.8</td></tr><tr><td> Black</td><td>8</td><td>7</td><td>97</td><td>8.9</td><td>188</td><td>9.5</td><td>729</td><td>7.7</td></tr><tr><td> Other</td><td>7</td><td>6.2</td><td>84</td><td>7.7</td><td>197</td><td>9.9</td><td>995</td><td>10.5</td></tr><tr><td colspan="9">Pathological grading</td></tr><tr><td> Grade I</td><td>12</td><td>10.5</td><td>89</td><td>8.2</td><td>127</td><td>6.4</td><td>581</td><td>6.1</td></tr><tr><td> Grade II</td><td>63</td><td>55.3</td><td>707</td><td>64.8</td><td>1459</td><td>73.4</td><td>6474</td><td>68.2</td></tr><tr><td> Grade III</td><td>11</td><td>9.6</td><td>95</td><td>8.7</td><td>190</td><td>9.6</td><td>1273</td><td>13.4</td></tr><tr><td> Grade IV</td><td>2</td><td>1.8</td><td>5</td><td>0.5</td><td>8</td><td>0.4</td><td>111</td><td>1.2</td></tr><tr><td> Unknown</td><td>26</td><td>22.8</td><td>195</td><td>17.8</td><td>205</td><td>10.2</td><td>1049</td><td>11.1</td></tr><tr><td colspan="9">Histotype</td></tr><tr><td> Adenocarcinoma</td><td>109</td><td>95.6</td><td>1058</td><td>97</td><td>1911</td><td>96.1</td><td>8685</td><td>91.5</td></tr><tr><td> Mucinous/Signet ring cell</td><td>5</td><td>44</td><td>33</td><td>3</td><td>78</td><td>3.9</td><td>803</td><td>8.5</td></tr><tr><td colspan="9">LNs examined</td></tr><tr><td> Median</td><td>6</td><td></td><td>8</td><td></td><td>11</td><td></td><td>12</td><td></td></tr><tr><td> Rang</td><td>1–21</td><td></td><td>1–25</td><td></td><td>1–28</td><td></td><td>1–35</td><td></td></tr></table> |
641fc238c42e8acddc74144eb958123f7134ab8811a0b00df80d6fb7596dba78.png | simple | <table><tr><td></td><td>Unit</td><td></td></tr><tr><td>Male:female</td><td><i>n</i> (%)</td><td>11 (26.2):31 (73.8)</td></tr><tr><td>Age</td><td>years</td><td>37 ± 12 (24–63)</td></tr><tr><td>Weight</td><td>kg</td><td>70.3 ± 11.5</td></tr><tr><td>BMI</td><td>kg/m<sup>2</sup></td><td>23.9 ± 3.1 (19.0–30.4)</td></tr><tr><td>Current smoker</td><td><i>n</i> (%)</td><td>2 (4.8)</td></tr><tr><td>Nutrition</td><td><i>n</i> (%)</td><td></td></tr><tr><td> Meat-based</td><td></td><td>37 (88.1)</td></tr><tr><td> Flexitarian<sup>a</sup></td><td></td><td>5 (11.9)</td></tr><tr><td>Medication</td><td><i>n</i> (%)</td><td></td></tr><tr><td> Thyroid hormone (L-thyroxine)</td><td></td><td>5 (11.9)</td></tr><tr><td> Hormone replacement therapy</td><td></td><td>2 (4.8)</td></tr><tr><td> Antidepressant (NDRI or SSRI)</td><td></td><td>2 (4.8)</td></tr><tr><td> Proton pump inhibitor</td><td></td><td>1 (2.4)</td></tr><tr><td> Oral anticoagulant and statins</td><td></td><td>1 (2.4)</td></tr><tr><td> Methylphenidate and antidepressant (NDRI)</td><td></td><td>1 (2.4)</td></tr><tr><td> Glucocorticoid<sup>b</sup></td><td></td><td>1 (2.4)</td></tr></table> |
9f512f54220e8a2e655d2525c8a2b1a593165cdb379efce4b809e5148a59538d.png | complex | <table><tr><td rowspan="2">Follow up</td><td>1wk</td><td colspan="2">2 m</td><td colspan="2">6 m</td></tr><tr><td>CCC size</td><td>CCC size</td><td>Change from 1 week(percentage)</td><td>CCC size</td><td>Change from 2 months(percentage)</td></tr><tr><td>Precizon (IOL A)</td><td>20.69 ± 1.50</td><td>17.17 ± 3.23</td><td>−3.53 ± 3.31 (17.06 ± 15.99%)</td><td>17.01 ± 3.11</td><td>− 0.16 ± 1.31 (0.64 ± 6.21%)</td></tr><tr><td>Microflex (IOL B)</td><td>21.70 ± 0.86</td><td>21.07 ± 1.50</td><td>− 0.62 ± 1.32 (2.87 ± 6.03%)</td><td>20.48 ± 1.09</td><td>− 0.60 ± 1.51 (2.47 ± 6.91%)</td></tr><tr><td>Asphina (IOL C)</td><td>21.43 ± 1.09</td><td>20.34 ± 1.60</td><td>−1.09 ± 1.53 (4.72 ± 6.10%)</td><td>19.86 ± 1.58</td><td>−0.48 ± 1.19 (2.12 ± 5.25%)</td></tr><tr><td><i>P-value</i>†</td><td>0.068</td><td>< 0.001</td><td>< 0.001</td><td>< 0.001</td><td>0.170</td></tr></table> |
17d3bee20e337b3138c685664052f32ace7de708c320fe8097a40cae6d26a585.png | simple | <table><tr><td>Drug(concentration)</td><td>Skin prick test(dilution factor)</td><td>Intradermal test(dilution factor)</td></tr><tr><td>Midazolam (5 mg/ml)</td><td>5 mg/ml (pure)</td><td>0.5 mg/ml (1:10)</td></tr><tr><td>Propofol (10 mg/ml)</td><td>10 mg/ml (pure)</td><td>1 mg/ml (1:10)</td></tr><tr><td>Ketamine (10 mg/ml)</td><td>10 mg/ml (pure)</td><td>1 mg/ml (1:10)</td></tr><tr><td>Thiopental (25 mg/ml)</td><td>25 mg/ml (pure)</td><td>2.5 mg/ml (1:10)</td></tr><tr><td>Etomidate (2 mg/ml)</td><td>2 mg/ml (pure)</td><td>0.2 mg/ml (1:10)</td></tr><tr><td>Morphine (10 mg/ml)</td><td>1 mg/ml (1:10)</td><td>0.01 mg/ml (1:1000)</td></tr><tr><td>Fentanyl (0.05 mg/ml)</td><td>0.05 mg/ml (pure)</td><td>0.005 mg/ml (1:10)</td></tr><tr><td>Remifentanil (0.05 mg/ml)</td><td>0.05 mg/ml (pure)</td><td>0.005 mg/ml (1:10)</td></tr><tr><td>Sufentanil (0.005 mg/ml)</td><td>0.005 mg/ml (pure)</td><td>0.0005 mg/ml (1:10)</td></tr><tr><td>Alfentanil (0.5 mg/ml)</td><td>0.5 mg/ml (pure)</td><td>0.05 mg/ml (1:10)</td></tr><tr><td>Atracurium (10 mg/ml)</td><td>1 mg/ml (1:10)</td><td>0.01 mg/ml (1:1000)</td></tr><tr><td>Cisatracurium (2 mg/ml)</td><td>2 mg/ml (pure)</td><td>0.02 mg/ml (1:100)</td></tr><tr><td>Rocuronium (10 mg/ml)</td><td>10 mg/ml (pure)</td><td>0.05 mg/ml (1:200)</td></tr><tr><td>Mivacurium (2 mg/ml)</td><td>0.2 mg/ml (1:10)</td><td>0.002 mg/ml (1:1000)</td></tr><tr><td>Pancuronium (2 mg/ml)</td><td>2 mg/ml (pure)</td><td>0.2 mg/ml (1:10)</td></tr><tr><td>Vecuronium (4 mg/ml)</td><td>4 mg/ml (pure)</td><td>0.4 mg/ml (1:10)</td></tr><tr><td>Suxamethonium (50 mg/ml)</td><td>10 mg/ml (1:5)</td><td>0.1 mg/ml (1:500)</td></tr></table> |
06a4316a9ba4c5e3150589b5b3d37eddc91cff1ec0f875dc3ab5b2d2025979cf.png | simple | <table><tr><td>Child</td><td>Deficiency of the limb</td><td>Associated anomaly</td><td>Relation of the relative</td><td>Limb anomaly of the relative</td></tr><tr><td>1</td><td>split hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>2</td><td>split hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>3</td><td>split hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>4</td><td>split hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>5</td><td>split hand of both upper limbs and split foot of both lower limbs</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>6</td><td>radial deficiency of left upper limb</td><td>Fanconi’s anemia</td><td>sibling</td><td>(not reported)</td></tr><tr><td>7</td><td>ulnar deficiency of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>8</td><td>transverse deficiency at the level of hand of right upper limb</td><td>none</td><td>sibling</td><td>(not reported)</td></tr><tr><td>9</td><td>split hand of right upper limb</td><td>none</td><td>mother</td><td>anomalies of radius and ulna</td></tr><tr><td>10</td><td>split hand of right upper limb</td><td>none</td><td>father</td><td>split hand</td></tr><tr><td>11</td><td>split hand of both upper limbs</td><td>none</td><td>father</td><td>split hand</td></tr><tr><td>12</td><td>split hand of left upper limb and tibial deficiency of both lower limbs</td><td>none</td><td>granduncle</td><td>split hand</td></tr><tr><td>13</td><td>split foot of right lower limb</td><td>none</td><td>someone other than sibling</td><td>(not reported)</td></tr><tr><td>14</td><td>ulnar deficiency of both upper limbs and split foot of both lower limbs</td><td>Leri-Weill syndrome</td><td>mother</td><td>Madelung deformity, and Leri-Weill syndrome</td></tr><tr><td>15</td><td>ulnar deficiency of both upper limbs and tibial deficiency of both lower limbs</td><td>none</td><td>mother and grandmother</td><td>upper limb anomaly</td></tr><tr><td>16</td><td>transverse deficiency at the level of hand of right upper limb</td><td>none</td><td>relative on the mother’s side</td><td>toe defect</td></tr><tr><td>17</td><td>transverse deficiency at the level of foot of both lower limbs</td><td>none</td><td>father and grandfather on the father’s side</td><td>anomaly of fifth finger</td></tr></table> |
3cb9e729529a4121b1fc4709b36d859fc5f030074aeb90b9aa711d5512249e0d.png | simple | <table><tr><td>Genus (family)</td><td>Order/suborder</td><td>Organelle genome</td><td>Inheritance</td><td>Reference</td></tr><tr><td><i>Equisetum</i> (Equisetaceae)</td><td>Equisetales</td><td>Plastome</td><td>Maternal</td><td>Guillon and Raquin, 2000</td></tr><tr><td><i>Ceratopteris</i> (Pteridaceae)</td><td>Polypodiales/Pteridineae</td><td>Plastome</td><td>Maternal</td><td>Adjie et al., 2007</td></tr><tr><td><i>Pellaea</i> (Pteridaceae)</td><td>Polypodiales/Pteridineae</td><td>Plastome and mitogenome</td><td>Maternal</td><td>Gastony and Yatskievych, 1992</td></tr><tr><td><i>Asplenium</i> (Aspleniaceae)</td><td>Polypodiales/Aspleniineae</td><td>Plastome</td><td>Maternal</td><td>Vogel et al., 1997</td></tr><tr><td><i>Deparia</i> (Athyriaceae)</td><td>Polypodiales/Aspleniineae</td><td>Plastome and mitogenome</td><td>Maternal</td><td>This study</td></tr></table> |
c2d61879219a1e6484f6f4208fa6230cf9a78c2f5a4971dd04e38b0848f5ddbc.png | simple | <table><tr><td>Date</td><td>Event</td></tr><tr><td>28 to 31 Oct 2008</td><td>Fifteenth Session of the IBC (2 days); Joint Session of the IBC and IGBC (2 days) (Paris)</td></tr><tr><td>9 to 10 Jul 2009</td><td>Sixth Session of the IGBC (Paris)</td></tr><tr><td>23 to 25 Nov 2009</td><td>Sixteenth Session of the IBC (Mexico City)</td></tr><tr><td>26 to 29 Oct 2010</td><td>Seventeenth Session of the IBC (2 days)*,; Joint Session of the IBC and IGBC (2 days)* (Paris)</td></tr><tr><td>31 May to 2 Jun 2011</td><td>Eighteenth Session of the IBC* (Baku)</td></tr><tr><td>5 to 6 Sep 2011</td><td>Seventh Session of the IGBC* (Paris)</td></tr></table> |
2dc1de5cf318b597870763b6c821206bf50a132cbc639ad9d29d9739b84720b4.png | complex | <table><tr><td><i>PredictiveVariables</i></td><td><i>HR</i></td><td><i>CI</i></td><td><i>P</i></td></tr><tr><td><i>Cyclin D1</i></td><td>10.864</td><td>1.055 – 86.250</td><td>0.03*</td></tr><tr><td> (baseline < 6.1)</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>Cyclin A</i></td><td>13.886</td><td>1.012 – 190.579</td><td>0.0490*</td></tr><tr><td> (baseline < 10.5)</td><td>-</td><td>-</td><td>-</td></tr><tr><td><i>Positive Lymph node metastasis</i></td><td>3.921</td><td>1.057 – 14.472</td><td>0.0410*</td></tr><tr><td><i>Stage IV</i></td><td>3.411</td><td>1.048 – 12.083</td><td>0.03*</td></tr><tr><td colspan="4"><i>Depth of invasion</i></td></tr><tr><td> T3, T4</td><td>5.408</td><td>0.449 – 65.080</td><td>0.1836</td></tr><tr><td colspan="4"><i>Age (years)</i></td></tr><tr><td>≥50</td><td>1.996</td><td>0.678 – 5.878</td><td>0.2310</td></tr><tr><td><i>Sex</i></td><td>0.910</td><td>0.315 – 2.358</td><td>0.8453</td></tr></table> |
69fa37cf648fb92c4eaf0931b5f1b44fc3cd94bd765efc977f1a6282024d4502.png | complex | <table><tr><td>Whole group, <i>n</i> = 92</td><td></td><td></td><td></td><td></td></tr><tr><td>Age (median) 59.5 years</td><td></td><td></td><td></td><td></td></tr><tr><td>Gender:</td><td>Male</td><td>32 (35 %)</td><td></td><td></td></tr><tr><td></td><td>Female</td><td>60 (65 %)</td><td></td><td></td></tr><tr><td>Treatment intent:</td><td>Palliative</td><td>7</td><td>Radical</td><td>85</td></tr><tr><td>N-stage</td><td>T-stage</td><td>No. of patients</td><td>% of total</td><td></td></tr><tr><td> N0</td><td>T1</td><td>19</td><td>20.7</td><td></td></tr><tr><td> N0</td><td>T2</td><td>37</td><td>40.2</td><td></td></tr><tr><td> N0</td><td>T3</td><td>20</td><td>21.7</td><td></td></tr><tr><td> N0</td><td>T4</td><td>6</td><td>6.5</td><td></td></tr><tr><td> N1</td><td>T3</td><td>1</td><td>1.1</td><td></td></tr><tr><td> N1</td><td>T4</td><td>4</td><td>4.4</td><td></td></tr><tr><td> N2</td><td>T3</td><td>3</td><td>3.3</td><td></td></tr><tr><td> N3</td><td>T3</td><td>1</td><td>1.1</td><td></td></tr><tr><td> N3</td><td>T4</td><td>1</td><td>1.1</td><td></td></tr><tr><td colspan="5">Radical treatment</td></tr><tr><td>Chemoradiotherapy plus boost, <i>n</i> = 52</td><td></td><td></td><td></td><td></td></tr><tr><td>Anal canal</td><td></td><td>Anal margin</td><td></td><td></td></tr><tr><td>Iridium boost, <i>n</i> = 36</td><td></td><td>Electron boost, <i>n</i> = 16</td><td></td><td></td></tr><tr><td>Age (median) 61 years</td><td></td><td>Age (median) 63 years</td><td></td><td></td></tr><tr><td>Stage</td><td>No. of patients (%)</td><td>Stage</td><td>No. of patients (%)</td><td></td></tr><tr><td> T1 N0</td><td>3 (8.3)</td><td>T1 N0</td><td>4 (25)</td><td></td></tr><tr><td> T2 N0</td><td>17 (47.2)</td><td>T2 N0</td><td>7 (43.8)</td><td></td></tr><tr><td> T3 N0</td><td>14 (38.9)</td><td>T3 N0</td><td>2 (12.5)</td><td></td></tr><tr><td> T2 N2</td><td>1 (2.8)</td><td> –</td><td>–</td><td></td></tr><tr><td> T3 N2</td><td>1 (2.8)</td><td> –</td><td>–</td><td></td></tr><tr><td>–</td><td>–</td><td>T4 N0</td><td>2 (12.5)</td><td></td></tr><tr><td>–</td><td>–</td><td>T4 N1</td><td>1 (6.2)</td><td></td></tr><tr><td>Radical treatment (other)</td><td></td><td></td><td></td><td></td></tr><tr><td>External beam radiotherapy alone</td><td>8</td><td></td><td></td><td></td></tr><tr><td>Chemoradiotherapy without boost</td><td>25</td><td></td><td></td><td></td></tr></table> |
f3befa0868f3a729dda32df32705da2f3164358b8bfdbe617a13acb207ba4013.png | simple | <table><tr><td></td><td>Cell line</td><td>EC50 of MTX</td></tr><tr><td>MCF-7</td><td>human breast adenocarcinoma</td><td>2.58 × 10<sup>−8</sup>M</td></tr><tr><td>MDA-MB 231</td><td>human breast adenocarcinoma</td><td>5.06 × 10<sup>−7</sup>M</td></tr><tr><td>T-24</td><td>human bladder carcinoma</td><td>8.07 × 10<sup>−8</sup>M</td></tr><tr><td>PANC-1</td><td>human pancreatic carcinoma</td><td>2.34 × 10<sup>−8</sup>M</td></tr><tr><td>HT29</td><td>human colon adenocarcinoma</td><td>6.09 × 10<sup>−8</sup>M</td></tr><tr><td>A375</td><td>human melanoma</td><td>3.37 × 10<sup>−8</sup>M</td></tr><tr><td>HT-1376</td><td>human bladder carcinoma</td><td>1.71 × 10<sup>−7</sup>M</td></tr><tr><td>OVCAR-3</td><td>human ovarian carcinoma</td><td>8.95 × 10<sup>−8</sup>M</td></tr></table> |
4d2ca6421488a92ec8b78c4845618a3401f2f106503b40c539f1c1f16f45a119.png | complex | <table><tr><td>Estimators</td><td colspan="3">WF population</td><td colspan="3">BF population</td></tr><tr><td>BREAST CANCER</td><td>Scenario 1</td><td>Scenario 2</td><td>Scenario 3</td><td>Scenario 1</td><td>Scenario 2</td><td>Scenario 3</td></tr><tr><td>Observed rates</td><td>0.973</td><td>0.974</td><td>0.975</td><td>0.956</td><td>0.964</td><td>0.965</td></tr><tr><td>Population-weighted average</td><td>0.967</td><td>0.943</td><td>0.968</td><td>0.887</td><td>0.761</td><td>0.910</td></tr><tr><td>Global Empirical Bayes</td><td>0.847</td><td>0.843</td><td>0.974</td><td>0.908</td><td>0.787</td><td>0.804</td></tr><tr><td>Local Empirical Bayes</td><td>0.964</td><td>0.952</td><td>0.971</td><td>0.899</td><td>0.782</td><td>0.921</td></tr><tr><td>Poisson kriging (true γ<sub>R</sub>(h))</td><td>0.971</td><td>0.972</td><td>0.947</td><td>0.716</td><td>0.842</td><td>0.887</td></tr><tr><td>Poisson kriging</td><td>0.965</td><td>0.913</td><td>0.940</td><td>0.761</td><td>0.927</td><td>0.803</td></tr><tr><td>CERVIX CANCER</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Observed rates</td><td>0.937</td><td>0.939</td><td>0.970</td><td>0.935</td><td>0.935</td><td>0.922</td></tr><tr><td>Population-weighted average</td><td>0.933</td><td>0.901</td><td>0.933</td><td>0.852</td><td>0.743</td><td>0.888</td></tr><tr><td>Global Empirical Bayes</td><td>0.875</td><td>0.870</td><td>0.973</td><td>0.833</td><td>0.785</td><td>0.787</td></tr><tr><td>Local Empirical Bayes</td><td>0.960</td><td>0.920</td><td>0.962</td><td>0.875</td><td>0.771</td><td>0.901</td></tr><tr><td>Poisson kriging (true γ<sub>R</sub>(h))</td><td>0.963</td><td>0.947</td><td>0.973</td><td>0.931</td><td>0.935</td><td>0.966</td></tr><tr><td>Poisson kriging</td><td>0.968</td><td>0.924</td><td>0.934</td><td>0.940</td><td>0.893</td><td>0.935</td></tr></table> |
6f941f48002860cf9a72f0121cc8fce78c2e41bdbe443e81f6a6f7e229ef503b.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">MCC 24</td><td colspan="3">CCC 46</td><td colspan="3">ACC 21</td><td colspan="3">MCC 46</td><td colspan="3">CCC 37</td><td colspan="3">MCC 35</td></tr><tr><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td><td>E</td><td>S</td><td>N</td></tr><tr><td>O/IR + FLL</td><td>40</td><td>35</td><td>15</td><td>59</td><td>21</td><td>4</td><td>43</td><td>34</td><td>7</td><td>48</td><td>29</td><td>6</td><td>41</td><td>37</td><td>4</td><td>25</td><td>42</td><td>15</td></tr><tr><td>Comparison%</td><td>39</td><td>36</td><td>15</td><td>62</td><td>18</td><td>4</td><td>47</td><td>30</td><td>7</td><td>53</td><td>24</td><td>6</td><td>46</td><td>32</td><td>4</td><td>30</td><td>39</td><td>13</td></tr></table> |
f10d7237b1de8a1ffb966fa36e95460a79ee4d84de915481d5bf8777b32f0a3f.png | simple | <table><tr><td>Strain name</td><td>Genotype</td><td>Reference</td></tr><tr><td>yMD7</td><td><i>MAT</i>a<i>ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg</i></td><td>This study</td></tr><tr><td></td><td><i>pep4::KanMX</i></td><td></td></tr><tr><td></td><td><i>MCM6::MCM6-3</i> × <i>FLAG (Nat-NT2)</i></td><td></td></tr><tr><td>yMD8</td><td><i>MAT</i>a<i>ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg</i></td><td>This study</td></tr><tr><td></td><td><i>pep4::KanMX</i></td><td></td></tr><tr><td></td><td><i>MCM6::MCM6-3</i> × <i>FLAG (Nat-NT2)</i></td><td></td></tr><tr><td></td><td><i>his3::HIS3pRS303/CDT1,GAL4</i></td><td></td></tr><tr><td></td><td><i>trp1::TRP1pRS304/MCM4, MCM5 leu2::LEU2pRS305/MCM6<sup>TC</sup>, MCM7 ura3::URA3pRS306/MCM2, CBP-MCM3</i></td><td></td></tr><tr><td>yMD9</td><td><i>MAT</i>a<i>ade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100</i>,</td><td>This study</td></tr><tr><td></td><td><i>cdc7-4, pep4:: Hyg</i>,</td><td></td></tr><tr><td></td><td><i>MCM10::MCM10-3</i> × <i>FLAG (Nat-NT2)</i></td><td></td></tr><tr><td></td><td><i>his3::HIS3pRS303/SLD3-13MYC</i>,</td><td></td></tr><tr><td></td><td><i>trp1::TRP1pRS304/SLD2, leu2::LEU2pRS305/SLD7, CDC45</i>,</td><td></td></tr><tr><td></td><td><i>ura3::URA3pRS306/DPB11</i></td><td></td></tr><tr><td>yMD16</td><td><i>MAT</i>a<i>/</i>α <i>ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10<sup>+</sup>/mcm10Δ472-571 (Nat-NT2)</i></td><td>This study</td></tr><tr><td>yMD17</td><td><i>MAT</i>a<i>/</i>α <i>ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10<sup>+</sup>/mcm10Δ472-571 (Nat-NT2) RAD9/rad9Δ::KanMX</i></td><td>This study</td></tr></table> |
97a29f38d180e4c3caa14553eed0f6a7cf471d5091ec275176aec44bddd00b1c.png | simple | <table><tr><td>CMP Solutions</td><td><i>c</i><sub>KDP</sub>/mM</td><td>MRR/(nm/min)</td><td>RMS/nm</td></tr><tr><td>1</td><td>0</td><td>605</td><td>3.1</td></tr><tr><td>2</td><td>10</td><td>476</td><td>2.3</td></tr><tr><td>3</td><td>20</td><td>334</td><td>1.7</td></tr><tr><td>4</td><td>30</td><td>251</td><td>1.5</td></tr><tr><td>5</td><td>40</td><td>187</td><td>1.8</td></tr><tr><td>6</td><td>50</td><td>156</td><td>2.3</td></tr><tr><td>7</td><td>80</td><td>142</td><td>2.7</td></tr><tr><td>8</td><td>100</td><td>138</td><td>2.8</td></tr></table> |
2875359f1940e6cd7d25209ea0c0513067289853c902d0d2486d8aac997f75d9.png | complex | <table><tr><td></td><td>Derivation <i>n</i> = 1420</td><td>Validation <i>n</i> = 3949</td><td><i>p</i>-value</td></tr><tr><td>Age<sup>a</sup></td><td>73.4 (10.0)</td><td>72.7 (10.7)</td><td>0.07</td></tr><tr><td>Sex (% male)</td><td>1275 (89.8)</td><td>3375 (85.5)</td><td>< 0.0001</td></tr><tr><td>FEV1%</td><td>45.2 (16.2)</td><td>45.3 (16.6)</td><td>0.76</td></tr><tr><td>FEV1%/FVC</td><td>52.5 (13.4)</td><td>52.5 (12.9)</td><td>0.79</td></tr><tr><td colspan="3">FEV1% categories</td><td>< 0.0001</td></tr><tr><td> ≥ 80%</td><td>33 (3.8)</td><td>62 (2.5)</td><td></td></tr><tr><td> < 80 - > 50</td><td>272 (31.2)</td><td>778 (31.0)</td><td></td></tr><tr><td>< 50 - > 30</td><td>217 (24.3)</td><td>1187 (47.3)</td><td></td></tr><tr><td>≤ 30</td><td>351 (40.2)</td><td>482 (19.2)</td><td></td></tr><tr><td>Body Mass Index<sup>a</sup></td><td>27.9 (5.3)</td><td>27.8 (5.7)</td><td>0.35</td></tr><tr><td colspan="3">Smoking habit</td><td>0.34</td></tr><tr><td> - Ever smoker</td><td>52 (4.3)</td><td>182 (4.9)</td><td></td></tr><tr><td> - Current smoker</td><td>343 (28.2)</td><td>977 (26.3)</td><td></td></tr><tr><td> - Ex-smoker</td><td>822 (67.5)</td><td>2554 (68.8)</td><td></td></tr><tr><td>Cigarette pack-years<sup>a</sup></td><td>55,82 (29.0)</td><td>51,99 (30.3)</td><td>0.003</td></tr><tr><td>Charlson Comorbidity Index<sup>a</sup></td><td>2,70 (1.8)</td><td>1,79 (1.7)</td><td>< 0.0001</td></tr><tr><td> 1–2</td><td>795 (56.0)</td><td>2865 (72.5)</td><td></td></tr><tr><td> ≥ 3</td><td>625 (44.0)</td><td>1084 (27.4)</td><td></td></tr><tr><td>Ischaemic heart disease</td><td>205 (15.7)</td><td>505 (12.8)</td><td>0.008</td></tr><tr><td>Cardiac failure</td><td>299 (23.0)</td><td>810 (20.5)</td><td>0.07</td></tr><tr><td>Peripheral vascular disease</td><td>221 (17.2)</td><td>494 (12.5)</td><td>< 0.0001</td></tr><tr><td>Cerebrovascular disease</td><td>146 (11.3)</td><td>380 (9.6)</td><td>0.09</td></tr><tr><td>Cardiac-Cerebro-Peripheral vascular disease</td><td>608 (46.2)</td><td>2217 (44.9)</td><td>0.41</td></tr><tr><td>Dementia</td><td>138 (3,49)</td><td>52 (4,04)</td><td>0.36</td></tr><tr><td>Diabetes mellitus</td><td>359 (26.2)</td><td>1032 (26.1)</td><td>0.95</td></tr><tr><td>Previous COPD hospitalization</td><td>1065 (76.7)</td><td>1881 (51.3)</td><td>< 0.0001</td></tr><tr><td>Mean of COPD-related admissions in the previous year</td><td>1.92 (2.0)</td><td>1.17 (1.8)</td><td>< 0.0001</td></tr><tr><td>pH at arrival</td><td>7.40 (0.1)</td><td>7.40 (0.1)</td><td>0.12</td></tr><tr><td>Acidaemia during admission</td><td>258 (19.3)</td><td>NA</td><td></td></tr><tr><td>PaO2 at arrival<sup>a</sup></td><td>59.1 (15.6)</td><td>60.4 (21.3)</td><td>0.79</td></tr><tr><td>PaCO2 at arrival<sup>a</sup></td><td>47.2 (14.4)</td><td>48.4 (15.7)</td><td>0.074</td></tr><tr><td>Length of stay<sup>a</sup></td><td>10.1 (6.9)</td><td>9.3 (7.0)</td><td>< 0.0001</td></tr></table> |
5433609c86d5b46fbdb1f80ed68792d056b34e4c77dd85dadb011a2765c43a20.png | simple | <table><tr><td></td><td>Men (<i>n</i> = 29)</td><td>Women (<i>n</i> = 31)</td></tr><tr><td>Age (years)</td><td>40 (21–64, sd = 11.48)</td><td>37 (23–57, sd = 9.77)</td></tr><tr><td>Body mass (kg)</td><td>80.1 (53.9–130.6, sd = 13.25)</td><td>61.7 (47.8–89.2, sd = 12.91)</td></tr><tr><td>Height (cm)</td><td>179.0 (159.1–190.0, sd = 7.81)</td><td>165.9 (154.4–184.2, sd = 7.90)</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>24.9 (20.7–39.3, sd = 3.46)</td><td>22.4 (17.2–28.8, sd = 3.31)</td></tr><tr><td>Skin tone (scale 1–6)</td><td>3.7 (1–5, sd = 1.39)</td><td>3.7 (1–6, sd = 1.25)</td></tr><tr><td>Wrist circumference (cm)</td><td>17.3 (16.0–21.0, sd = 1.11)</td><td>15.4 (13.5–17.5, sd = 1.30)</td></tr><tr><td>VO<sub>2</sub>max (ml/kg/min)</td><td>52.8 (38.2–66.6, sd = 8.48)</td><td>45.3 (31.7–56.5, sd = 7.62)</td></tr></table> |
ded94dc35f8cdccfb09310797537210b6dd7be41dbf7f630f9a231be88918708.png | simple | <table><tr><td></td><td>KEGG ID</td><td>KEGG term</td><td>Hypergeometric<i>P</i>-value</td><td>Corrected<i>P</i>-value (BF)</td></tr><tr><td></td><td>hsa05200</td><td>Pathways in cancer</td><td>6.16E−08</td><td>1.23E−05</td></tr><tr><td></td><td>hsa04110</td><td>Cell cycle</td><td>7.96E−08</td><td>1.58E−05</td></tr><tr><td></td><td>hsa04144</td><td>Endocytosis</td><td>1.34E−07</td><td>2.67E−05</td></tr><tr><td>Down</td><td>hsa04520</td><td>Adherens junction</td><td>2.55E−07</td><td>5.08E−05</td></tr><tr><td></td><td>hsa04310</td><td>Wnt signaling pathway</td><td>1.16E−06</td><td>2.31E−04</td></tr><tr><td></td><td>hsa05220</td><td>Chronic myeloid leukemia</td><td>4.39E−06</td><td>8.73E−04</td></tr><tr><td></td><td>hsa04114</td><td>Oocyte meiosis</td><td>4.90E−06</td><td>9.75E−04</td></tr><tr><td></td><td>hsa05200</td><td>Pathways in cancer</td><td>2.47E−09</td><td>5.14E−07</td></tr><tr><td></td><td>hsa05220</td><td>Chronic myeloid leukemia</td><td>4.54E−08</td><td>9.45E−06</td></tr><tr><td></td><td>hsa04144</td><td>Endocytosis</td><td>3.80E−07</td><td>7.91E−05</td></tr><tr><td></td><td>hsa05215</td><td>Prostate cancer</td><td>7.45E−07</td><td>1.55E−04</td></tr><tr><td>Up</td><td>hsa04110</td><td>Cell cycle</td><td>7.71E−07</td><td>1.60E−04</td></tr><tr><td></td><td>hsa04115</td><td>p53 signaling pathway</td><td>2.31E−06</td><td>4.80E−04</td></tr><tr><td></td><td>hsa04120</td><td>Ubiquitin mediated proteolysis</td><td>2.33E−06</td><td>4.84E−04</td></tr><tr><td></td><td>hsa05210</td><td>Colorectal cancer</td><td>2.51E−06</td><td>5.22E−04</td></tr><tr><td></td><td>hsa04520</td><td>Adherens junction</td><td>2.82E−06</td><td>5.87E−04</td></tr></table> |
7f8729a02d768d2ab42447e2ecb43e47610c7a70357b888b5df69462c6b2ed25.png | complex | <table><tr><td rowspan="2">plasma DBP (<i>μ</i>g/mL)</td><td colspan="2">GAgP group (<i>n</i> = 59)</td><td colspan="2">Control group (<i>n</i> = 58)</td></tr><tr><td><i>r </i></td><td><i>P</i> value</td><td><i>r </i></td><td><i>P</i> value</td></tr><tr><td>Mean BI</td><td>0.1588</td><td>0.251</td><td>0.048</td><td>0.768</td></tr><tr><td>Mean PD</td><td>−0.1347</td><td>0.327</td><td>−0.190</td><td>0.216</td></tr><tr><td>Mean AL</td><td>−0.164</td><td>0.230</td><td>None</td><td>—</td></tr><tr><td>Severe sites %</td><td>−0.167</td><td>0.233</td><td>None</td><td>—</td></tr></table> |
4c41e43aa2b324f367de1b1aa57ae79b8c5a4ce14e33c28a753120a1ecf3a69f.png | simple | <table><tr><td>NCC material</td><td>After 48 h</td><td>After 336 h</td><td>After 336 h + freezing and thawing</td></tr><tr><td>Untreated</td><td>−</td><td>−</td><td>+</td></tr><tr><td>10 kGy</td><td>+</td><td>+</td><td>+</td></tr><tr><td>20 kGy</td><td>+/− <sup>1</sup></td><td>+</td><td>+</td></tr><tr><td>30 kGy</td><td>−</td><td>+/− <sup>1</sup></td><td>+</td></tr><tr><td>40 kGy</td><td>−</td><td>+/− <sup>1</sup></td><td>+</td></tr><tr><td>50 kGy</td><td>−</td><td>−</td><td>+</td></tr><tr><td>60 kGy</td><td>−</td><td>−</td><td>−</td></tr></table> |
a933e072a8010018458aca96e0c3472b93547f41f44f0f6e0e2dbe42987df62b.png | simple | <table><tr><td>Group</td><td>Mean calluses width, mm ± SD</td><td>Mean calluses length, mm ± SD</td><td>Regeneration zones ± SD</td><td>Embryogenesis appearance, %</td></tr><tr><td>Control</td><td>4.18 ± 1.36</td><td>6.22 ± 0.67</td><td>1.24 ± 0.48</td><td>20</td></tr><tr><td>AgNPs</td><td>5.37 ± 3.47</td><td>7.00 ± 2.54</td><td>2.01 ± 0.98</td><td>34</td></tr><tr><td>AuNPs</td><td>6.39 ± 2.82</td><td>6.55 ± 2.36</td><td>3.29 ± 1.07</td><td>49</td></tr></table> |
4f9db0b7f2d4761467f767ff81ff0ad317c3c7dc06a12cf53eaf5a13c773d1be.png | simple | <table><tr><td>Surgery</td><td>Ratio between post-discharge SSIs and in-hospital SSIs</td></tr><tr><td>Vascular surgery</td><td>0</td></tr><tr><td>Breast surgery</td><td>3,4</td></tr><tr><td>Cesarean section</td><td>2,5</td></tr><tr><td>Cholecistectomy</td><td>1,2</td></tr><tr><td>Gastric surgery</td><td>0,4</td></tr><tr><td>Appendectomy</td><td>0,2</td></tr><tr><td>Colon surgery</td><td>0,1</td></tr><tr><td>Hernia repair</td><td>1,4</td></tr><tr><td>Abdominal hysterectomy</td><td>0,6</td></tr><tr><td>Vaginal hysterectomy</td><td>1</td></tr></table> |
fc0f1932aaa4617e32418f5652e9399f5f421cb1fe0c1123d415330a5034b842.png | complex | <table><tr><td>Outcome Measures</td><td>Importance</td><td>Validity</td><td>Scientific soundness</td><td>Usability</td><td>Feasibility</td><td>Ranking</td></tr><tr><td>CGI-SCH</td><td>HIGH</td><td>HIGH</td><td>MED</td><td>MED</td><td>HIGH</td><td rowspan="8">1</td></tr><tr><td>Degree of involvement in vocational rehabilitation</td><td>HIGH</td><td>HIGH</td><td>MED</td><td>MED</td><td>HIGH</td></tr><tr><td>Brief Psychiatric Rating Scale</td><td>MED</td><td>HIGH</td><td>MED</td><td>MED</td><td>MED</td></tr><tr><td>Degree of Independent Living</td><td>HIGH</td><td>HIGH</td><td>MED</td><td>LOW</td><td>MED</td></tr><tr><td>PANSS</td><td>MED</td><td>MED</td><td>MED</td><td>MED</td><td>LOW</td></tr><tr><td>Service user Satisfaction Survey Responses</td><td>HIGH</td><td>LOW</td><td>LOW</td><td>MED</td><td>MED</td></tr><tr><td>Development of Metabolic Syndrome/Diabetes</td><td>HIGH</td><td>HIGH</td><td>MED</td><td>MED</td><td>MED</td></tr><tr><td>GAF Score</td><td>MED</td><td>MED</td><td>MED</td><td>MED</td><td>MED</td></tr><tr><td colspan="7">Process Adherence Measures</td></tr><tr><td> Percentage of Service users on Multiple Antipsychotics (excluding clozapine)</td><td>MED</td><td>HIGH</td><td>MED</td><td>HIGH</td><td>MED</td><td>1</td></tr><tr><td> Percentage of service users who have metabolic monitoring at recommended intervals</td><td>HIGH</td><td>HIGH</td><td>HIGH</td><td>HIGH</td><td>LOW</td><td>2</td></tr><tr><td> Percentage of service users referred for supported employment/vocational services</td><td>HIGH</td><td>MED</td><td>HIGH</td><td>HIGH</td><td>HIGH</td><td>3</td></tr><tr><td> Percentage of service users referred to CBT for psychosis</td><td>HIGH</td><td>MED</td><td>HIGH</td><td>HIGH</td><td>HIGH</td><td rowspan="5">4</td></tr><tr><td> Percentage of service users on recommended dosages (within therapeutic range) of antipsychotic medication</td><td>MED</td><td>MED</td><td>MED</td><td>HIGH</td><td>LOW</td></tr><tr><td> Percentage of service users with a summary of previous medication trials</td><td>MED</td><td>MED</td><td>MED</td><td>HIGH</td><td>MED</td></tr><tr><td> Percentage of first-episode service users who have had a MRI brain</td><td>MED</td><td>LOW</td><td>LOW</td><td>HIGH</td><td>HIGH</td></tr><tr><td> Percentage of service users that have an annual physical exam</td><td>MED</td><td>LOW</td><td>LOW</td><td>HIGH</td><td>HIGH</td></tr></table> |
3ae47eecde0121925586e7f2a179799bcb56f86d8d19c01ba93731b46835b496.png | simple | <table><tr><td>Ingenuity Canonical Pathway<sup>a</sup></td><td>C2<sup>b</sup></td><td>C3</td><td>C4</td></tr><tr><td>Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F</td><td>3.47E-08</td><td></td><td></td></tr><tr><td>Communication between Innate and Adaptive Immune Cells</td><td>6.17E-08</td><td></td><td></td></tr><tr><td>TREM1 Signaling</td><td>1.1E-07</td><td></td><td></td></tr><tr><td>Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F</td><td>2.09E-07</td><td></td><td></td></tr><tr><td>Role of Cytokines in Mediating Communication between Immune Cells</td><td>0.000331</td><td></td><td></td></tr><tr><td>MSP-RON Signaling Pathway</td><td>0.000331</td><td></td><td></td></tr><tr><td>Dendritic Cell Maturation</td><td>0.000427</td><td></td><td></td></tr><tr><td>Acute Phase Response Signaling</td><td>0.002399</td><td></td><td></td></tr><tr><td>Crosstalk between Dendritic Cells and Natural Killer Cells</td><td>0.002455</td><td></td><td></td></tr><tr><td>IL-17A Signaling in Fibroblasts</td><td>0.002754</td><td></td><td></td></tr><tr><td>Chemokine Signaling</td><td>0.012303</td><td></td><td></td></tr><tr><td>Glucocorticoid Receptor Signaling</td><td>0.016218</td><td></td><td></td></tr><tr><td>NF-kB Signaling</td><td>0.016982</td><td></td><td></td></tr><tr><td>LXR/RXR Activation</td><td>0.032359</td><td></td><td></td></tr><tr><td>p38 MAPK Signaling</td><td>0.033884</td><td></td><td></td></tr><tr><td>IL-6 Signaling</td><td>0.038019</td><td></td><td></td></tr><tr><td>IL-12 Signaling and Production in Macrophages</td><td>0.038905</td><td></td><td></td></tr><tr><td>G-Protein Coupled Receptor Signaling</td><td></td><td>0.006166</td><td></td></tr><tr><td>Role of PI3K/AKT Signaling in the Pathogenesis of Influenza</td><td></td><td>0.019055</td><td></td></tr><tr><td>Crosstalk between Dendritic Cells and Natural Killer Cells</td><td></td><td>0.039811</td><td></td></tr><tr><td>Activation of IRF by Cytosolic Pattern Recognition Receptors</td><td></td><td></td><td>1.58E-11</td></tr><tr><td>Interferon Signaling</td><td></td><td></td><td>1.23E-10</td></tr><tr><td>Role of RIG1-like Receptors in Antiviral Innate Immunity</td><td></td><td></td><td>2.24E-05</td></tr><tr><td>Retinoic acid Mediated Apoptosis Signaling</td><td></td><td></td><td>0.000148</td></tr><tr><td>Role of PKR in Interferon Induction and Antiviral Response</td><td></td><td></td><td>0.000832</td></tr><tr><td>Role of JAK1, JAK2 and TYK2 in Interferon Signaling</td><td></td><td></td><td>0.002884</td></tr><tr><td>Role of MAPK Signaling in the Pathogenesis of Influenza</td><td></td><td></td><td>0.032359</td></tr><tr><td>IL-10 Signaling</td><td>0.012303</td><td>0.00537</td><td></td></tr><tr><td>Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses</td><td>3.31E-05</td><td></td><td>3.24E-08</td></tr><tr><td>Role of IL-17F in Allergic Inflammatory Airway Diseases</td><td>0.000257</td><td></td><td>0.010965</td></tr><tr><td>Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza</td><td>0.000132</td><td>0.000891</td><td>0.006918</td></tr></table> |
8e44a476eef7f00401a957e278480426f348ff78a3ee41c9d64153c3cfb2df88.png | simple | <table><tr><td>Characteristic</td><td>Burkina Faso*</td><td>Senegal*</td><td>Niger*</td><td>Ghana*</td></tr><tr><td>Surveillance design</td><td>Prospective</td><td>Retrospective</td><td>Retrospective</td><td>Prospective</td></tr><tr><td>Geographic extent</td><td>Three districts</td><td>Dakar</td><td>Niamey</td><td>Northern area</td></tr><tr><td>Surveillance population</td><td>880,000</td><td>950,000</td><td>550,000</td><td>140,000</td></tr><tr><td>Rural/Urban</td><td>Both</td><td>Urban</td><td>Urban</td><td>Rural</td></tr><tr><td>Study years</td><td>2002-2005</td><td>1970-1979</td><td>1981-1996</td><td>1998-2003</td></tr><tr><td>Microbiological methods</td><td>Culture, antigen detection, PCR</td><td>Culture</td><td>Culture, antigen detection</td><td>Culture, antigen detection</td></tr><tr><td>Number of confirmed pneumococcal meningitis cases</td><td>249</td><td>983</td><td>934</td><td>76</td></tr><tr><td>Percent of cases occurring during dry/epidemic season months of Dec-Apr<sup>†</sup></td><td>75%</td><td>49%</td><td>63%</td><td>69%</td></tr><tr><td>Two months with peak number of cases (percent of total)<sup>†</sup></td><td>Jan-Feb (38%)</td><td>Feb-Mar (21%)</td><td>Feb-Mar (31%)</td><td>Dec-Jan (35%)</td></tr><tr><td>Relation of pneumococcal to meningococcal seasonal peak</td><td>Similar</td><td>2 months in advance</td><td>1 month in advance</td><td>1 to 2 months in advance</td></tr><tr><td>13-valent conjugate vaccine coverage of isolated serotypes</td><td></td><td></td><td></td><td></td></tr><tr><td>Age <5 years</td><td>67%</td><td>78% (age<2 yrs)</td><td>No serotype data</td><td>100%</td></tr><tr><td>Age 5+ years</td><td>77%</td><td>94% (age 2+ yrs)</td><td>No serotype data</td><td>98%</td></tr><tr><td>Reference</td><td>4,5</td><td>9</td><td>8</td><td>7</td></tr></table> |
b1c98e163e84880e0adfbfb440c1f5edfe682615714d00fff57ec17dbf3dd55c.png | simple | <table><tr><td>Algal species</td><td>Protein</td><td>Carbohydrates</td><td>Lipids</td></tr><tr><td><i>Anabaena cylindrica</i>[96]</td><td>43–56</td><td>25–30</td><td>4–7</td></tr><tr><td><i>Aphanizomenon flos-aquae</i>[96]</td><td>62</td><td>23</td><td>3</td></tr><tr><td><i>Chlamydomonas reinhardtii</i>[96]</td><td>48</td><td>17</td><td>21</td></tr><tr><td><i>Chlorella minutissima</i>[21]</td><td>9–24</td><td>14–42</td><td>31–57</td></tr><tr><td><i>Auxenochlorella protothecoides</i>[97]</td><td>11–26</td><td>17–24</td><td>25–54</td></tr><tr><td><i>Auxenochlorella protothecoides</i>[21]</td><td>36–38</td><td>41–52</td><td>11–23</td></tr><tr><td><i>Chlorella pyrenoidosa</i>[96]</td><td>57</td><td>26</td><td>2</td></tr><tr><td><i>Chlorella emersonii</i>[21]</td><td>28–32</td><td>11–41</td><td>29–63</td></tr><tr><td><i>Chlorella sorokiniana</i>[21]</td><td>42–45</td><td>32–38</td><td>20–22</td></tr><tr><td><i>Chlorella vulgaris</i>[96]</td><td>51–58</td><td>12–17</td><td>14–22</td></tr><tr><td><i>Chlorella vulgaris</i>[21]</td><td>7–29</td><td>51–55</td><td>18–40</td></tr><tr><td><i>Dunaliella salina</i>[96]</td><td>57</td><td>32</td><td>6</td></tr><tr><td><i>Euglena gracilis</i>[96]</td><td>39–61</td><td>14–18</td><td>14–20</td></tr><tr><td><i>Nannochloropsis</i> sp.[98]</td><td>23–59</td><td>5–17</td><td>9–62</td></tr><tr><td><i>Porphyridium cruentum</i>[96]</td><td>28–39</td><td>40–57</td><td>9–14</td></tr><tr><td><i>Scenedesmus obliquus</i>[96]</td><td>50–56</td><td>10–17</td><td>12–14</td></tr><tr><td><i>Spirogyra</i> sp.[96]</td><td>6–20</td><td>33–64</td><td>11–21</td></tr><tr><td><i>Arthrospira maxima</i>[96]</td><td>60–71</td><td>13–16</td><td>6–7</td></tr><tr><td><i>Spirulina platensis</i>[96]</td><td>46–63</td><td>8–14</td><td>4–9</td></tr><tr><td><i>Synechococcus</i> sp.[96]</td><td>63</td><td>15</td><td>11</td></tr></table> |
88446de0973a26c0ad92a04ecf1af666688e72a8ce72488a764dd2f9927ebfc0.png | complex | <table><tr><td rowspan="3">Factors</td><td colspan="3">Post-progression survival</td></tr><tr><td>Hazard ratio</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td>Age (years) at the beginning of first-line treatment</td><td>0.98</td><td>0.94–1.02</td><td>0.47</td></tr><tr><td>Chemoradiotherapy (sequential/concurrent)</td><td>2.25</td><td>0.66–7.04</td><td>0.18</td></tr><tr><td>Best response at second-line treatment (NonPD/PD)</td><td>0.22</td><td>0.10–0.47</td><td>< 0.01</td></tr><tr><td>Distant metastases at recurrence (yes/no)</td><td>2.42</td><td>1.18–5.22</td><td>0.01</td></tr><tr><td>Administration of platinum-based agents after first-line treatment (yes/no)</td><td>0.92</td><td>0.41–1.98</td><td>0.83</td></tr><tr><td>Number of regimens after first-line treatment</td><td>0.75</td><td>0.56–0.98</td><td>0.04</td></tr></table> |
7465409247879ef130e80f9b8fb2cb5d68e2f4bd03c9c26fc3511b6111fb00c2.png | simple | <table><tr><td>Route</td><td><i>N</i></td><td>(%)</td></tr><tr><td>Internet</td><td>2511</td><td>(42.0)</td></tr><tr><td>TV or Movie</td><td>3185</td><td>(53.2)</td></tr><tr><td>Retail Store</td><td>2138</td><td>(35.7)</td></tr><tr><td>Billboard</td><td>810</td><td>(13.6)</td></tr><tr><td>Vehicle</td><td>483</td><td>(8.1)</td></tr><tr><td>Event</td><td>686</td><td>(11.5)</td></tr><tr><td>Magazine or newspaper</td><td>2062</td><td>(34.9)</td></tr></table> |
2b8b816ebc6cc7b0e62585f3c2874ca5afa578fd984e30270fa966feaa99cb72.png | simple | <table><tr><td>SLE patients</td><td>No lupus nephritis(α)</td><td>Lupus nephritis(β)</td><td>p-value</td></tr><tr><td>Gender (female: male)</td><td>53:3</td><td>17:5</td><td>0.03*</td></tr><tr><td></td><td>mean± standard deviation (<i>n</i> = 56)</td><td>mean± standard deviation (<i>n</i> = 22)</td><td></td></tr><tr><td>Age (year)</td><td>28.72±14.87</td><td>28.3±14.79</td><td>0.91</td></tr><tr><td>Leukocytes (×1000/ml)</td><td>5.73±2.92</td><td>7.53±3.57</td><td>0.03*</td></tr><tr><td>Hemoglobulin (mg/dL)</td><td>12.04±1.56</td><td>11.60±2.46</td><td>0.45</td></tr><tr><td>Neutrophil (%)</td><td>62.49±11.95</td><td>73.07±12.68</td><td>0.002*</td></tr><tr><td>Lymphocyte (%)</td><td>29.36±11.00</td><td>19.77±10.67</td><td>0.002*</td></tr><tr><td>Platelets (1000/μL)</td><td>254.47±124.81</td><td>226.24±70.82</td><td>0.34</td></tr><tr><td>Alanine aminotransferase (U/dL)</td><td>16.88±12.84</td><td>25±0.21</td><td>0.21</td></tr><tr><td>Erythrocyte Sediment Rate (mm/hr)</td><td>28.84±29.15</td><td>27.07±23.66</td><td>0.84</td></tr><tr><td>Albumin (mg/dL)</td><td>4.25±0.42</td><td>3.27±0.89</td><td>0.01*</td></tr><tr><td>anti-dsDNA (U/dL)</td><td>255.58±195.41</td><td>307.99±156.27</td><td>0.40</td></tr><tr><td>C3 (mg/dL)</td><td>85.69±25.70</td><td>75.95±23.61</td><td>0.16</td></tr><tr><td>C4 (mg/dL)</td><td>18.62±18.28</td><td>13.44±6.05</td><td>0.24</td></tr><tr><td>Creatinine (mg/dL)</td><td>0.63±0.12</td><td>1.35±1.26</td><td>0.03*</td></tr><tr><td>Urine protein/Creatinine</td><td>168.58±149.48</td><td>1568.89±1468.85</td><td>0.003*</td></tr></table> |
08347f0e7444b132300154ee1bcca2f2d62892fc8b02f09563394dfd1aee85d3.png | simple | <table><tr><td>Species</td><td>Exon A</td><td>Exon B</td><td>Exon C</td><td>Exon D</td><td>Exon E</td><td>Exon F</td><td>Identity</td></tr><tr><td>Horse</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>130</td><td>100.0</td></tr><tr><td>Cat</td><td>1477</td><td>86</td><td>206</td><td>133</td><td>134</td><td>139</td><td>83.0</td></tr><tr><td>Dog</td><td>1477</td><td>86</td><td>206</td><td>133</td><td>134</td><td>139</td><td>81.1</td></tr><tr><td>Cattle</td><td>1474</td><td>86</td><td>206</td><td>130</td><td>131</td><td>145</td><td>79.2</td></tr><tr><td>Elephant</td><td>1510</td><td>86</td><td>206</td><td>133</td><td>137</td><td>187</td><td>75.1</td></tr><tr><td>Human</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>187</td><td>81.9</td></tr><tr><td>Chimpanzee</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>187</td><td>79.7</td></tr><tr><td>Orangutan</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>187</td><td>81.2</td></tr><tr><td>Rhesus</td><td>1480</td><td>86</td><td>206</td><td>133</td><td>134</td><td>187</td><td>79.7</td></tr><tr><td>Mouse</td><td>1474</td><td>86</td><td>206</td><td>133</td><td>137</td><td>172</td><td>66.3</td></tr><tr><td>Rat</td><td>1489</td><td>86</td><td>206</td><td>133</td><td>131</td><td>172</td><td>65.5</td></tr><tr><td>Guinea Pig</td><td>1462</td><td>86</td><td>206</td><td>133</td><td>134</td><td>187</td><td>69.7</td></tr><tr><td>Opossum</td><td>1453</td><td>86</td><td>206</td><td>129</td><td>131</td><td>139</td><td>56.5</td></tr><tr><td>Chicken</td><td>1402</td><td>89</td><td>191</td><td>124</td><td>122</td><td>136</td><td>37.3</td></tr></table> |
2edb4d60d6e22abaf32211a0fd109e4d6d3c7c91db1de2365021af7c6aa3cdc7.png | simple | <table><tr><td></td><td>Autism Spectrum Disorder <i>M</i> (<i>SD</i>)</td><td>Down Syndrome <i>M</i> (<i>SD</i>)</td><td>Typical development <i>M</i> (<i>SD</i>)</td></tr><tr><td>Exploratory play</td><td>0.29 (1.49)</td><td>-0.11 (0.66)</td><td>0.17 (0.83)</td></tr><tr><td>(1) Unitary functional activity</td><td>1.67 (2.09)</td><td>0.49 (0.78)</td><td>0.73 (0.86)</td></tr><tr><td>(2) Inappropriate combinatorial activity</td><td>-0.44 (0.30)</td><td>-0.38 (0.36)</td><td>-0.20 (0.62)</td></tr><tr><td>(3) Appropriate combinatorial activity</td><td>0.25 (1.3)</td><td>-0.15 (0.68)</td><td>0.36 (0.82)</td></tr><tr><td>(4) Transitional play</td><td>-0.31 (0.39)</td><td>-0.42 (0.28)</td><td>-0.19 (0.61)</td></tr><tr><td>Symbolic play</td><td>-0.18 (0.79)</td><td>-0.12 (0.68)</td><td>-0.05 (0.69)</td></tr><tr><td>(5) Self-directed pretense</td><td>0.07 (0.85)</td><td>0.02 (0.69)</td><td>0.23 (0.80)</td></tr><tr><td>(6) Other-directed pretense</td><td>-0.12 (0.92)</td><td>-0.29 (0.34)</td><td>-0.12 (0.42)</td></tr><tr><td>(7) Sequential pretense</td><td>-0.11 (0.74)</td><td>0.28 (0.96)</td><td>0.22 (0.86)</td></tr><tr><td>(8) Substitution pretense</td><td>-0.55 (0.00)</td><td>-0.52 (0.11)</td><td>-0.54 (0.09)</td></tr></table> |
e940e440732d5a3ad2183fcb1a373041c029b5fc2b9d2940357799ebcb081e85.png | complex | <table><tr><td colspan="2">Cohort 3</td><td>Patients with ∆ reticulin and/or collagen<sup>a</sup> (<i>N</i> = 7)</td><td>Patients with no ∆ collagen or reticulin (<i>N</i> = 51)</td></tr><tr><td colspan="2">Age, median (Q1, Q3), years</td><td>47 (30, 60)</td><td>44 (33, 61)</td></tr><tr><td colspan="2">ITP duration, median (Q1, Q3), years</td><td>4.1 (1.2, 9.1)</td><td>2.2 (1.2, 7.1)</td></tr><tr><td colspan="2">Prior splenectomy rate, <i>n</i> (%)</td><td>2 (29)</td><td>17 (33)</td></tr><tr><td rowspan="2">Platelet response<sup>b</sup>, median (Q1, Q3)</td><td>Time to first platelet response, weeks</td><td>15 (7, 21)<sup>c</sup></td><td>3 (2, 8)<sup>d</sup></td></tr><tr><td>Weeks with platelet response, %</td><td>5 (0, 28)</td><td>38 (28, 76)</td></tr><tr><td rowspan="3">Exposure<sup>e</sup>, median (Q1, Q3)</td><td>Average weekly dose, μg/kg</td><td>9 (7, 9)</td><td>2 (1, 5)</td></tr><tr><td>Maximum weekly dose, μg/kg</td><td>10 (9, 10)</td><td>4 (3, 10)</td></tr><tr><td>Cumulative dose, μg/kg</td><td>1207 (204, 1358)</td><td>345 (136, 610)</td></tr></table> |
14f81461f0f9993500fad766ae21b5c94ced6e64f205832dd2cc25f8fdf8f5bd.png | simple | <table><tr><td>Pollen recipient (♀)</td><td>Pollen donor (♂)</td><td>Number of flowers</td><td>Number of fruits</td><td>Fruit set (%)</td><td>Mean number of seeds per fruit</td><td>Seed viability (%)</td><td>Mean number of viable seeds per fruit<sup>a</sup></td></tr><tr><td><i>B. crispa</i></td><td><i>B. crispa</i></td><td>20</td><td>11</td><td>55</td><td>65.50</td><td>34</td><td>22.27</td></tr><tr><td></td><td><i>B. officinalis</i></td><td>24</td><td>14</td><td>58</td><td>8.00</td><td>68</td><td>5.44</td></tr><tr><td></td><td>Putative hybrid</td><td>27</td><td>15</td><td>55</td><td>2.20</td><td>70</td><td>1.54</td></tr><tr><td><i>B. officinalis</i></td><td><i>B. crispa</i></td><td>32</td><td>2</td><td>6</td><td>1.00</td><td>0</td><td>0.00</td></tr><tr><td></td><td><i>B. officinalis</i></td><td>23</td><td>10</td><td>43</td><td>65.00</td><td>91</td><td>59.15</td></tr><tr><td></td><td>Putative hybrid</td><td>37</td><td>18</td><td>48</td><td>1.94</td><td>57</td><td>1.11</td></tr><tr><td>Putative hybrid</td><td><i>B. crispa</i></td><td>31</td><td>19</td><td>61</td><td>2.79</td><td>0</td><td>0.00</td></tr><tr><td></td><td><i>B. officinalis</i></td><td>38</td><td>32</td><td>84</td><td>4.63</td><td>53</td><td>2.45</td></tr><tr><td></td><td>Putative hybrid</td><td>45</td><td>7</td><td>15</td><td>0.43</td><td>0</td><td>0.00</td></tr></table> |
19600379292ab6ee8ec50e297db7c6bc6a50364eb4f3705cb2e3318165f40f83.png | simple | <table><tr><td></td><td>control</td><td>LBBB</td></tr><tr><td>n</td><td>100</td><td>33</td></tr><tr><td>males, n (%)</td><td>64 (64.0%)</td><td>23 (69.7%)</td></tr><tr><td>age, years</td><td>52.5 ± 16.9</td><td>69.7 ± 9.1</td></tr><tr><td>QRS, ms</td><td>82.4 ± 4.2</td><td>149.7 ± 15.5</td></tr><tr><td>LVEF, %</td><td>59.7 ± 2.1</td><td>34.6 ± 12.3</td></tr><tr><td>heart rate, min<sup>-1</sup></td><td>72.0 ± 10.8</td><td>69.3 ± 11.3</td></tr><tr><td>cardiomyopathy</td><td></td><td></td></tr><tr><td> ischemic, n (%)</td><td>-</td><td>17 (51.5%)</td></tr><tr><td> dilated, n (%)</td><td>-</td><td>10 (30.3%)</td></tr><tr><td> hypertensive, n (%)</td><td>-</td><td>2 (6.1%)</td></tr><tr><td> valvular, n (%)</td><td>-</td><td>1 (3.0%)</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.